

**Funding Opportunities Monthly Edition
Aug 2022 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Aug 2022. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110642	Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)	Fogarty International Center/NIH/DHHS	PAR-22-151	22-Aug-2022	1,400,000 USD
	<p>Contact Name Geetha P Bansal Ph.D.</p> <p>Contact Telephone 301-496-1492</p> <p>Contact Email geetha.bansal@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Aug-2022 , 22-Aug-2023 , 22-Aug-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, data science, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined high priority HIV scientific area aligned with NIH HIV/AIDS research priorities (NOT-OD-20-018) at a specific LMIC institution and collaborating LMIC partner institutions. This FOA allows qualified Trainees to serve as the lead investigator of an independent clinical trial; or to propose a separate ancillary study to an existing trial under the mentorship of an appropriate clinical researcher or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>				
110643	Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed)	Fogarty International Center/NIH/DHHS	PAR-22-152	22-Aug-2022	56,000 USD
	<p>Contact Name Geetha P Bansal Ph.D.</p> <p>Contact Telephone 301-496-1492</p> <p>Contact Email geetha.bansal@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Aug-2022 , 22-Aug-2023 , 22-Aug-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Fogarty HIV Research Training (HIVRT) Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>			
110644	Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed)	Fogarty International Center/NIH/DHHS	PAR-22-153	22-Aug-2022	282,000 USD
	Contact Name	Geetha P Bansal Ph.D.			
	Contact Telephone	301-496-1492			
	Contact Email	geetha.bansal@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Aug-2022 , 22-Aug-2023 , 22-Aug-2024			
	Synopsis	<p>The overall goal of the Fogarty HIV Research Training Program (HIVRT) is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries. This Funding Opportunity Announcement (FOA) encourages collaborative applications from U.S. and LMIC institutions to develop training programs to achieve technical, administrative and financial management expertise required for one of several research infrastructure support functions considered critical to a successful high-quality research environment. These are: a) research administration and management, b) research integrity oversight, c) ethical review of research for the protection of human subjects, d) laboratory animal welfare oversight, e) health sciences library and information services, f) information and communications technology systems (ICT) for research, g) biostatistics and data analysis, h) technology transfer and intellectual property protection, and i) any area not mentioned above that justifiably will contribute to enhancing Institutional services that can support research activities. Research infrastructure support training programs will maximize previous investments, further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.</p>			
111615	RFA-RM-22-023 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Partnership for Innovation Research Projects (U01 Clinical Trial Not Allowed)	Fogarty International Center/NIH/DHHS	RFA-RM-22-023	29-Aug-2022 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Brad Newsome, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-480-8389</p> <p>Contact Email DS-IU01Mailbox@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Aug-2022 [Optional][LOI/Pre-App], 28-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks applications for Partnership for Innovation Research Projects as part of a broader ongoing initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. DS-I Africa Partnership for Innovation Research Projects are meant to support discrete research projects led by investigators in Africa to expand the DS-I Africa consortium. Applicants will propose innovative health data science research and solutions in Africa with the ability to advance population-relevant, affordable, acceptable, and scalable data science solutions and, in the long-term, demonstrate the ability of these solutions to improve health in Africa. Applications should propose partnership with a non-academic partner that enhances the potential impact of the research. Since one goal of this FOA is to expand the DS-I Africa consortium, either the applicant organization or proposed partner should not be a current member of the consortium. Additionally, these projects are aimed to enhance the career pipeline and retention of health data scientists in Africa by supporting a minimum number of new and early-stage investigators. Applications must be submitted from African academic or other non-profit organizations. Proposed partnerships with organizations outside the applicant institution can include all types of organizations in Africa, the U.S., or other countries.</p>				
111614	<p>RFA-RM-22-022 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Research Education Program (UE5 Clinical Trial Not Allowed)</p>	Fogarty International Center/NIH/DHHS	RFA-RM-22-022	29-Aug-2022 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Laura Povlich, Ph.D.</p> <p>Contact Telephone 301-827-2227</p> <p>Contact Email DS-IAfricaUE5@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Aug-2022 [Optional][LOI/Pre-App], 28-Sep-2022</p> <p>Synopsis The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that complement and/or enhance the training of a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

workforce to meet the biomedical, behavioral and clinical research needs of the Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. Applications are encouraged that propose innovative, state-of-the-art, hands-on programs that advance the goal of DS-I Africa. The courses should focus on activities that target educational needs or gaps in the DS-I Africa consortium, and thus applicants must have support from current DS-I Africa awardees. Applications must be submitted from African academic or other non-profit organizations.

109867	FCO -- SBSA -- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2023	National Cancer Institute/NIH/DHHS	75N91022R00006	22-Aug-2022	Not Specified
--------	--	------------------------------------	----------------	-------------	---------------

Contact Name	Cherie Wells
Contact Telephone	
Contact Email	ncioasbir@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Aug-2022
Synopsis	<p>The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Development of devices or diagnostic technologies for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation, rare cancers with a survival rate of less than 50% are encouraged, and rare cancers would be defined as including all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers Preliminary data is not required; however, the idea should have a sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurship skills and to develop or refine a business model and commercialization plan. This solicitation is a Concept Award program that could serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. Background for the SBIR</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>program can be found in the Small Business Administration’s policy directive found here: https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf This is a total small business set-aside solicitation. Only proposals from eligible small businesses will be considered for award. This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. To be eligible as a small business, the business concern may have no more than 500 employees, including the employees of its Affiliates. See 13 C.F.R. § 121.702. Other requirements apply, as well – see the SBA’s SBIR Policy Directive for further eligibility requirements – https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf This solicitation includes an interim date for submission and consideration of white papers which will allow the NCI to provide feedback on whether or not the proposed idea falls within the scope of what this solicitation is seeking. NOTE – SBIR / STTR GRANT OPPORTUNITIES Other SBIR and STTR contract and grant opportunities are also available. Companies are encouraged to review https://seed.nih.gov/small-business-funding/find-funding For general information regarding the NCI SBIR Program, please refer to https://sbir.cancer.gov/</p>				
108207	RFA-CA-22-010 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-010	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD
	Contact Name	Kelly Crotty, Ph.D.			
	Contact Telephone	240-760-7997			
	Contact Email	kelly.crotty@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108206	RFA-CA-22-009 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-009	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone 240-760-7997</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
107240	RFA-CA-22-004 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-22-004	23-Aug-2022 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Kelly Crotty Ph.D.</p> <p>Contact Telephone 240-760-7997</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022 [Optional][LOI/Pre-App], 22-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

107563	RFA-CA-22-001 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-22-001	23-Aug-2022 [Optional][LOI/Pre-App]	450,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-760-7997
Contact Email	kelly.crotty@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 22-Sep-2022
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.</p> <p>Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

107564	RFA-CA-22-002 -- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-22-002	23-Aug-2022 [Optional][LOI/Pre-App]	900,000 USD
--------	---	------------------------------------	---------------	--	----------------

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-760-7997
Contact Email	kelly.crotty@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 22-Sep-2022
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>

108205	RFA-CA-22-008 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-008	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-760-7997
Contact Email	kelly.crotty@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI P01 program projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
108204	<p>RFA-CA-22-007 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-22-007	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Kelly Crotty, Ph.D.</p> <p>Contact Telephone 240-760-7997</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
108203	<p>RFA-CA-22-006 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-22-006	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108202	RFA-CA-22-005 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-005	23-Aug-2022 [Optional][LOI/Pre-App]	150,000 USD

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-760-7997
Contact Email	kelly.crotty@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Contact Name	Kelly Crotty, Ph.D.
Contact Telephone	240-760-7997
Contact Email	kelly.crotty@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107238	RFA-CA-22-003 -- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-22-003	23-Aug-2022 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name Kelly Crotty Ph.D.</p> <p>Contact Telephone 240-760-7997</p> <p>Contact Email kelly.crotty@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022 [Optional][LOI/Pre-App], 22-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>				
110275	RFA-CA-22-025 -- SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-025	05-Jul-2022 [Optional][LOI/Pre-App]	4,000,000 USD
	<p>Contact Name Jonathan Franca-Koh, PhD, MBA</p> <p>Contact Telephone 240-618-0984</p> <p>Contact Email francaohjc@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jul-2022 [Optional][LOI/Pre-App], 05-Aug-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.</p>				
110269	RFA-CA-22-016 -- Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-016	27-Aug-2022 [Optional][LOI/Pre-App]	2,250,000 USD
	<p>Contact Name Anju Singh, B.V.Sc, Ph.D.</p> <p>Contact Telephone 240-276-7603</p> <p>Contact Email anju.singh@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Aug-2022 [Optional][LOI/Pre-App], 27-Sep-2022</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107760	Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	24-Jun-2022	Not Specified
	<p>Contact Name Sallie J. Weaver, PhD, MHS</p> <p>Contact Telephone 240-276-6254</p> <p>Contact Email sallie.weaver@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jun-2022 , 26-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 28-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 26-Apr-2023 , 07-May-2023 , 25-May-2023 , 26-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 08-Oct-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.</p>				
108323	Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	24-Jun-2022	Not Specified
	<p>Contact Name Veronica Chollette, RN, MS</p> <p>Contact Telephone 240-276-6969</p> <p>Contact Email cholletv@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jun-2022 , 26-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 22-Oct-2022 , 08-Nov-2022 , 28-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 26-Apr-2023 , 07-May-2023 , 25-May-2023 , 26-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 28-Dec-2023 , 07-Jan-2024 , 25-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 08-Oct-2024

Synopsis
 The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.

106733	Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention	National Cancer Institute/NIH/DHHS	NOT-CA-21-121	25-Jun-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Phillip J. Daschner, MSc
Contact Telephone	240-276-6227
Contact Email	pd93u@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Jun-2022 , 20-Jul-2022 , 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 25-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 25-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 25-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 25-Jun-2024 , 07-Sep-2024
Synopsis	This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.

110931	Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-22-085	24-Jun-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Ron Johnson, Ph.D.
--------------	--------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6250</p> <p>Contact Email rjohnso2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Jun-2022 , 20-Jul-2022 , 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.</p>				
104079	RFA-HL-22-001 -- T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-001	14-Aug-2022 [Optional][LOI/Pre-App]	1,610,000 USD
	<p>Contact Name Traci Mondoro, PhD</p> <p>Contact Telephone 301-435-0050</p> <p>Contact Email NHLBI_Blood_Training@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Aug-2022 [Optional][LOI/Pre-App], 13-Sep-2022 , 29-Jan-2023 [Optional][LOI/Pre-App], 28-Feb-2023 , 14-Aug-2023 [Optional][LOI/Pre-App], 13-Sep-2023 , 29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse backgrounds, including those from groups that are nationally underrepresented in cardiovascular, pulmonary, hematologic and sleep disorders research across the career development continuum by providing support to institutions that promote diversity. The NHLBI's T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Service Award Program intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for these populations. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

104783	RFA-HL-22-012 -- Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-012	10-Jul-2022 [Optional][LOI/Pre-App]	770,000 USD
--------	---	--	---------------	--	----------------

Contact Name	Paul Cotton, Ph.D., RDN
Contact Telephone	301-435-0202
Contact Email	paul.cotton@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Jul-2022 [Optional][LOI/Pre-App], 09-Aug-2022 , 24-Jan-2023 [Optional][LOI/Pre-App], 23-Feb-2023 , 10-Jul-2023 [Optional][LOI/Pre-App], 09-Aug-2023 , 24-Jan-2024 [Optional][LOI/Pre-App], 23-Feb-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that can enrich the pool of individuals from diverse backgrounds, including nationally underrepresented groups, who will be available to compete for research opportunities in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

108574	RFA-HL-23-010 -- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-010	21-Jul-2022	600,000 USD
--------	---	--	---------------	-------------	----------------

Contact Name	Mike Pieck, Ph.D.
Contact Telephone	301-827-7986

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jul-2022 , 18-Aug-2022 , 21-Nov-2022 , 21-Dec-2022 , 21-Feb-2023 , 18-Apr-2023 , 21-Jul-2023 , 18-Aug-2023 , 21-Nov-2023 , 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.</p>				
108576	<p>RFA-HL-23-012 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-012	21-Jul-2022	700,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email nhlbi_catalyze@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-Jul-2022 , 18-Aug-2022 , 21-Nov-2022 , 21-Dec-2022 , 21-Feb-2023 , 18-Apr-2023 , 21-Jul-2023 , 18-Aug-2023 , 21-Nov-2023 , 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

108577	RFA-HL-23-013 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-013	21-Jul-2022	750,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Mike Pieck, Ph.D.
Contact Telephone	301-827-7986
Contact Email	nhlbi_catalyze@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	21-Jul-2022 , 18-Aug-2022 , 21-Nov-2022 , 21-Dec-2022 , 21-Feb-2023 , 18-Apr-2023 , 21-Jul-2023 , 18-Aug-2023 , 21-Nov-2023 , 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024
Synopsis	This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

108578	RFA-HL-23-014 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-014	21-Jul-2022	500,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Mike Pieck, Ph.D.
Contact Telephone	301-827-7986
Contact Email	nhlbi_catalyze@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	21-Jul-2022 , 18-Aug-2022 , 21-Nov-2022 , 21-Dec-2022 , 21-Feb-2023 , 18-Apr-2023 , 21-Jul-2023 , 18-Aug-2023 , 21-Nov-2023 , 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
108575	RFA-HL-23-011 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-011	21-Jul-2022	1,050,000 USD
	Contact Name	Mike Pieck, Ph.D.			
	Contact Telephone	301-827-7986			
	Contact Email	nhlbi_catalyze@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jul-2022 , 18-Aug-2022 , 21-Nov-2022 , 21-Dec-2022 , 21-Feb-2023 , 18-Apr-2023 , 21-Jul-2023 , 18-Aug-2023 , 21-Nov-2023 , 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.			
109308	RFA-HL-23-018 -- Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-018	09-Aug-2022	150,000 USD
	Contact Name	Margaret Ochocinska, PhD			
	Contact Telephone	301-827-8285			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email ochocinm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Aug-2022 , 19-Oct-2022 , 07-Dec-2022 , 20-Jun-2023 , 09-Aug-2023 , 19-Oct-2023 , 07-Dec-2023 , 20-Jun-2024 , 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.</p>				
095566	RFA-HG-20-037 -- Advancing Genomic Medicine Research (R21 Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-037	02-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ms. Christine Chang</p> <p>Contact Telephone 301-480-2255</p> <p>Contact Email christine.chang2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>				
095564	RFA-HG-20-036 -- Advancing Genomic Medicine Research (R01 Clinical Trial Optional)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-036	02-Jul-2022 [Optional][LOI/Pre-App]	3,000,000 USD
	<p>Contact Name Ms. Christine Chang</p> <p>Contact Telephone 301-480-2255</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email christine.chang2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>				
103017	NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)	National Human Genome Research Institute/NIH/DHHS	PAR-21-143	08-Aug-2022	Not Specified
	<p>Contact Name Tina Gatlin, Ph.D.</p> <p>Contact Telephone 301-480-2280</p> <p>Contact Email gatlincl@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 08-Dec-2022 , 08-Apr-2023 , 08-Aug-2023 , 08-Dec-2023 , 08-Apr-2024</p> <p>Synopsis The purpose of the NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) is to support a defined pathway across career stages for talented graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences. This two-phased award will facilitate completion of a doctoral dissertation (F99) and transition to a strong postdoctoral research position (K00) focused on the scientific, medical, ethical, social and/or legal areas of genomics research. It is anticipated that successful completion of this phased award program will provide students sufficient scientific and career development activities to set them on the path to becoming independent genomics researchers.</p>				
108325	Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients' Use of Genomic Information	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-011	01-Aug-2022	Not Specified
	<p>Contact Name Ken Wiley, Jr., Ph.D.</p> <p>Contact Telephone 301-435-5540</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email ken.wiley@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 13-Mar-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing a Notice of Special Interest (NOSI) to encourage applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.</p>				
109723	RFA-AI-22-022 -- Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-022	04-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Keith Crawford, Ph.D.</p> <p>Contact Telephone 240-669-2816</p> <p>Contact Email keith.crawford@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Jul-2022 [Optional][LOI/Pre-App], 03-Aug-2022</p> <p>Synopsis This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged.</p>				
088718	International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-108	15-Jul-2022	625,000 USD
	<p>Contact Name Glen C. McGugan, Jr., Ph.D.</p> <p>Contact Telephone 240-627-3314</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email gm233g@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jul-2022 , 19-Aug-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date.</p>				
111121	RFA-AI-22-034 -- Understanding the Clinical History of Bacterial Sexually Transmitted Infections (STI) to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-034	13-Aug-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Leah Vincent, Ph.D.</p> <p>Contact Telephone 301-761-7365</p> <p>Contact Email leah.vincent@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Aug-2022 [Optional][LOI/Pre-App], 12-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies on the clinical history of three sexually transmitted infections (STIs): syphilis, gonorrhea, and chlamydia. Improved understanding of the human immune response after infection through diagnosis and treatment will provide a much-needed knowledge base to accelerate vaccine and diagnostic development.</p>				
110792	RFA-AR-23-002 -- NIAMS Rheumatic Diseases Research Resource-based Centers (P30 - Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR-23-002	14-Aug-2022 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name Aron Marquitz, Ph.D.</p> <p>Contact Telephone 301-435-1240</p> <p>Contact Email aron.marquitz@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Aug-2022 [Optional][LOI/Pre-App], 13-Sep-2022</p> <p>Synopsis The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for rheumatic diseases research areas within its mission. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on rheumatic diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.</p>				
106576	Notice of Special Interest (NOSI): Promoting Pain Research Within the NIAMS Mission Areas	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-22-007	01-Jul-2022	Not Specified
	<p>Contact Name Leslie K. Derr, Ph.D.</p> <p>Contact Telephone 301-402-4735</p> <p>Contact Email leslie.derr@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jul-2022 , 12-Jul-2022 , 20-Jul-2022 , 12-Aug-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 01-Nov-2022 , 12-Nov-2022 , 18-Nov-2022 , 12-Dec-2022 , 22-Jun-2025</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving grant applications focused on pain within the NIAMS mission areas.</p>				
109946	Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-22-006	08-Aug-2022	Not Specified
	<p>Contact Name I. George Zubal, Ph.D.</p> <p>Contact Telephone 301-827-5168</p> <p>Contact Email igeorge.zubal@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 12-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 08-Dec-2022 , 12-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 12-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 12-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing nuclear medicine imaging technologies to achieve more cost-efficient clinical Single-Photon Emission Computerized Tomography (SPECT) applications.</p>				
110928	RFA-HD-23-001 -- NICHD Neonatal Research Network (NRN): Data Coordinating Center (U24 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-001	12-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Nahida Chakhtoura, MD, MsGH</p> <p>Contact Telephone 301-435-6872</p> <p>Contact Email nahida.chakhtoura@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022</p> <p>Synopsis The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Neonatal Research Network (NRN). This Funding Opportunity Announcement (FOA) invites applications for a NRN Data Coordinating Center; a separate FOA invites applications for NRN Clinical Centers.</p>				
110974	RFA-HD-23-017 -- NICHD Maternal-Fetal Medicine Units (MFMU) Network: Data Coordinating Center (U24 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-017	12-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Nahida Chakhtoura, M.D.</p> <p>Contact Telephone 301-435-6872</p> <p>Contact Email nahida.chakhtoura@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022			
	Synopsis	The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Maternal-Fetal Medicine Units (MFMU) Network. This Funding Opportunity Announcement (FOA) invites applications for a MFMU Network Data Coordinating Center; a separate FOA invites applications for MFMU Network Clinical Centers.			
110971	RFA-HD-23-016 -- NICHD Maternal-Fetal Medicine Units (MFMU) Network: Clinical Centers (UG1 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-016	12-Jul-2022 [Optional][LOI/Pre-App]	1,540,000 USD
	Contact Name	Nahida Chakhtoura, M.D.			
	Contact Telephone	301-435-6872			
	Contact Email	nahida.chakhtoura@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022			
	Synopsis	The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Maternal-Fetal Medicine Units (MFMU) Network. This Funding Opportunity Announcement (FOA) invites applications for MFMU Network Clinical Centers; a separate FOA invites applications for a MFMU Network Data Coordinating Center.			
111363	NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-026	10-Jul-2022 [Optional][LOI/Pre-App]	1,000,000 USD
	Contact Name	Denise Russo, PhD			
	Contact Telephone	301-435-6871			
	Contact Email	denise.russo@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 10-Jul-2022 [Optional][LOI/Pre-App], 10-Aug-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.</p>				
110929	RFA-HD-23-002 -- NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-002	12-Jul-2022 [Optional][LOI/Pre-App]	1,540,000 USD
	<p>Contact Name Nahida Chakhtoura, MD, MsGH</p> <p>Contact Telephone 301-435-6872</p> <p>Contact Email nahida.chakhtoura@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022</p> <p>Synopsis The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Neonatal Research Network (NRN). This Funding Opportunity Announcement (FOA) invites applications for NRN Clinical Centers; a separate FOA invites applications for a NRN Data Coordinating Center.</p>				
105294	Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-040	10-Aug-2022	Not Specified
	<p>Contact Name John V. Ilekis, PhD</p> <p>Contact Telephone 301-435-6895</p> <p>Contact Email ilekij@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022 , 07-Sep-2022</p> <p>Synopsis Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to help address a number of major gaps in knowledge.

101701	NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-108	08-Aug-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs during the transition from predoctoral student to postdoctoral scholar. This phased award program will facilitate completion of predoctoral dual degree dentist scientist training (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enhance dual degree dentist scientists' research career trajectories This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

102061	NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-060	08-Aug-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
109830	<p>RFA-DK-21-033 -- KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 - Independent Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-21-033	01-Aug-2022	Not Specified
	<p>Contact Name Christine Maric-Bilkan, Ph.D</p> <p>Contact Telephone 301-435-0486</p> <p>Contact Email christine.maric-bilkan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 , 30-Nov-2022 , 30-Mar-2023 , 01-Aug-2023 , 30-Nov-2023 , 02-Apr-2024 , 01-Aug-2024 , 03-Dec-2024 , 01-Apr-2025</p> <p>Synopsis The purpose of the Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Transition Award (F99/K00) is to recruit truly exceptional graduate students, who are currently not involved in Kidney, Urology or Hematology (K, U or H) research, and provide them a stable transition into a postdoctoral research experience focused on K, U, or H research. Strong candidates will bring novel approaches and diverse perspectives from fields including, but not limited to, engineering, statistics, data science, imaging, biochemistry, neuroscience and genetics. Graduate students who are already involved in K, U, or H research are not eligible for this F99/K00 award and are instead encouraged to apply for the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31, PA-21-051). Prospective applicants are strongly encouraged to contact the NIDDK Program Official early in the process to discuss eligibility and program goals. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085817	Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F32)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-379	08-Aug-2022	Not Specified
	<p>Contact Name Arthur L. Castle, Ph.D.</p> <p>Contact Telephone 301-594-7719</p> <p>Contact Email castlea@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is to enable promising postdoctoral fellows to obtain interdisciplinary training from outstanding faculty sponsors in bioinformatics and scientific research relevant to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
085810	Bioinformatics Interdisciplinary Predoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F31)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-378	08-Aug-2022	Not Specified
	<p>Contact Name Arthur L. Castle, Ph.D.</p> <p>Contact Telephone 301-594-7719</p> <p>Contact Email castlea@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022</p> <p>Synopsis This funding opportunity is to enable promising predoctoral fellows to obtain interdisciplinary training during the dissertation phase of their training from outstanding faculty sponsors in bioinformatics and scientific research relevant to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>			
111735	RFA-DK-22-509 -- Limited Competition for the Continuation of the NIDDK Diabetic Foot Consortium - Clinical Research Units (U01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-22-509	17-Jul-2022 [Optional][LOI/Pre-App]	1,710,000 USD
	Contact Name	Teresa L. Z. Jones, M.D.			
	Contact Telephone	301-435-2996			
	Contact Email	teresa.jones@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Jul-2022 [Optional][LOI/Pre-App], 17-Aug-2022			
	Synopsis	<p>The Diabetic Foot Consortium (DFC) is the first clinical network for the study of diabetic foot ulcers (DFUs)— a common, expensive, and debilitating complication of diabetes that leads to over 100,000 amputations in the United States every year. The DFC was started to address this significant public health problem by building a research infrastructure and validating biomarkers to predict healing or recurrence of DFUs. This Limited Competition Funding Opportunity Announcement (FOA) calls for the renewal of the Clinical Research Units (CRUs) for their support of an expansion of the mission of the DFC with the following goals: 1) develop and validate biomarkers for DFUs; 2) accelerate advances in DFU standard care; 3) characterize the role of social determinants of health for DFU healing and recurrence; and 4) build on the DFC infrastructure through ancillary studies and satellite sites. Future research may involve clinical trials and studies on the pathophysiology and prevention of DFUs. All clinical protocol activities will occur at the CRUs. They will recruit participants, collect longitudinal data, images and biosamples and send these data and biosamples to the Data Coordinating Center and Biomarker Analysis Units. They will also collaborate with Satellite sites to accelerate the pace of the DFC studies. As members of the Steering Committee, they will provide leadership in developing protocols and setting priorities for the DFC to best leverage its resources to improve clinical research and care for DFUs.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Jul-2022	275,000 USD
	<p>Contact Name Martha I. Barnes, MS</p> <p>Contact Telephone 919-541-3335</p> <p>Contact Email barnes@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>Synopsis This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>				
110746	RFA-ES-22-004 -- SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-22-004	16-Aug-2022	Not Specified
	<p>Contact Name Kathy Ahlmark</p> <p>Contact Telephone 984-287-3231</p> <p>Contact Email ahlmark@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Aug-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Technology-enhanced training products for the health and safety training of: hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biological hazard response, infectious disease</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

response, and medical waste cleanup; emergency responders in disasters; and worker resiliency training. Technology-enhanced training products as defined by the Worker Training Program (WTP) include, but are not limited to, online training, mobile device training, virtual reality, and serious gaming. These advanced technologies complement all phases of training from development to evaluation and can enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of WTP. The major objective of the NIEHS WTP is to prevent work related harm by training workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.

110435	IDeA Clinical Research Resource Center (U24 Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-22-150	26-Aug-2022 [Optional][LOI/Pre-App]	9,000,000 USD
--------	---	---	------------	--	---------------

Contact Name	Lumy Sawaki-Adams, M.D., Ph.D.
Contact Telephone	
Contact Email	lumy.sawaki-adams@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Aug-2022 [Optional][LOI/Pre-App], 26-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support an IDeA Clinical Research Resource Center (I-CRRC) that addresses two specific needs for increasing capacity to conducting clinical trials and complex observational studies in IDeA states. I-CRRC will 1) strengthen communication and develop collaborations between health research institutions in IDeA-eligible states and clinical trial sponsors, and 2) develop clinical trial and observational study coordinators with the knowledge and skills to manage clinical studies.

108741	Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-021	25-Jun-2022	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Veerasamy (Ravi) Ravichandran, Ph.D.
Contact Telephone	
Contact Email	Veerasamy.ravichandra@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 03-Oct-2022 , 05-Oct-2022 , 12-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 27-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.</p>			
108717	<p>Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required)</p>	National Institute of Mental Health/NIH/DHHS	PAR-22-112	25-Aug-2022	2,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Pim Brouwers, Ph.D.</p> <p>240-627-3863</p> <p>ebrouwer@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>25-Aug-2022 , 23-Dec-2022</p> <p>NIMH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). See "Determination that a Public Health Emergency Exists Nationwide as the Result of the 2019 Novel Coronavirus" as renewed in "Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic". This Funding Opportunity Announcement (FOA) aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic through rapid acceleration of research to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions to respond to new and worsening mental illness and HIV-related outcomes among those who experience COVID-19 as well as the broader population impacted by the pandemic. All research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting health disparities.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
108721	Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-22-113	25-Aug-2022	2,250,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Pim Brouwers, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-627-3863</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>ebrouwer@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>25-Aug-2022 , 23-Dec-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>NIMH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). See "Determination that a Public Health Emergency Exists Nationwide as the Result of the 2019 Novel Coronavirus" as renewed in "Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic". This Funding Opportunity Announcement (FOA) aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic through 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development. Research is anticipated to be informed by and directed towards vulnerable populations based on evidence of preexisting and worsened health disparities.</td> </tr> </table>					Contact Name	Pim Brouwers, Ph.D.	Contact Telephone	240-627-3863	Contact Email	ebrouwer@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	25-Aug-2022 , 23-Dec-2022	Synopsis	NIMH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). See "Determination that a Public Health Emergency Exists Nationwide as the Result of the 2019 Novel Coronavirus" as renewed in "Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic". This Funding Opportunity Announcement (FOA) aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic through 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development. Research is anticipated to be informed by and directed towards vulnerable populations based on evidence of preexisting and worsened health disparities.
Contact Name	Pim Brouwers, Ph.D.																		
Contact Telephone	240-627-3863																		
Contact Email	ebrouwer@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	25-Aug-2022 , 23-Dec-2022																		
Synopsis	NIMH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). See "Determination that a Public Health Emergency Exists Nationwide as the Result of the 2019 Novel Coronavirus" as renewed in "Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic". This Funding Opportunity Announcement (FOA) aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic through 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development. Research is anticipated to be informed by and directed towards vulnerable populations based on evidence of preexisting and worsened health disparities.																		
100189	NIMH AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-20-308	25-Aug-2022	7,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Christopher Gordon, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-627-3867</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>cgordon1@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>25-Aug-2022 , 25-Aug-2023</td> </tr> </table>					Contact Name	Christopher Gordon, PhD	Contact Telephone	240-627-3867	Contact Email	cgordon1@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	25-Aug-2022 , 25-Aug-2023		
Contact Name	Christopher Gordon, PhD																		
Contact Telephone	240-627-3867																		
Contact Email	cgordon1@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	25-Aug-2022 , 25-Aug-2023																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to provide infrastructure support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science.</p>			
100187	Developmental AIDS Research Centers on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-20-307	25-Aug-2022	3,000,000 USD
	Contact Name	Christopher Gordon, PhD			
	Contact Telephone	240-627-3867			
	Contact Email	cgordon1@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Aug-2022 , 25-Aug-2023			
	Synopsis	<p>The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support Developmental HIV/AIDS Research Centers (D-ARC). The D-ARC is intended to provide infrastructure support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. The intent of D-ARC support is that the proposed core activities will allow the D-ARC to compete successfully for a full NIMH AIDS Research Center (ARC) after the D-ARC award period.</p>			
111480	Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22-172	10-Aug-2022	Not Specified
	Contact Name	Ashley Smith, Ph.D.			
	Contact Telephone	301-496-4406			
	Contact Email	ashley.smith2@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	10-Aug-2022 , 07-Sep-2022 , 09-Dec-2022 , 07-Jan-2023 , 11-Apr-2023 , 07-May-2023 , 10-Aug-2023 , 07-Sep-2023 , 11-Dec-2023 , 07-Jan-2024 , 10-Apr-2024 , 07-May-2024 , 09-Aug-2024 , 07-Sep-2024 , 10-Dec-2024 , 07-Jan-2025 , 10-Apr-2025 , 07-May-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from diverse backgrounds, including those from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This FOA provides support to complete a mental health-related doctoral research project and includes funds not readily available in NRSA predoctoral (F31) awards, which limit support to stipends, tuition and fees, and institutional allowance.			
102539	Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment and Cure	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-105	25-Jun-2022	Not Specified
	Contact Name	Collene Lawhorn, Ph.D.			
	Contact Telephone	301-828-7186			
	Contact Email	collene.lawhorn@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024			
	Synopsis	The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.			
108843	Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-095	22-Jun-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	NIMHResearchOnAggres@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 15-Nov-2022 , 08-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 22-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 15-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 25-Oct-2023 , 15-Nov-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research on the etiology, risks for, and prevention of interpersonal aggression and violence against others.</p>				
097096	RFA-NS-21-001 -- NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-001	29-Aug-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Beth-Anne Sieber, PhD</p> <p>Contact Telephone 301- 496-5680</p> <p>Contact Email Beth-Anne.Sieber@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Aug-2022 [Optional][LOI/Pre-App], 28-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson's disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Applicants will identify an overall research theme that directly addresses a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge. Udall Centers also serve as local resources by providing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Required components of this FOA include: an Overall section describing the Center theme, vision and organization; three or more Research Projects, plus a dedicated Udall Catalyst research project led by an early career researcher poised to become an expert in PD research; an Administrative Core; at least one integrated Research Core that is essential to and accelerates the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>progress of two or more Research Projects; a mission statement for career enhancement of Center investigators, and a plan for periodic outreach to the local patient/advocacy community, including specific outreach events to convey Center research advances. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. Considerable synergy must be evident among Center research projects and cores, such that the Center structure is required for successful completion of the aims. Funding decisions will focus on those applications most likely to make significant contributions to PD research, as well as those with greatest potential to collaborate effectively across the Udall Centers program.</p>			
111120	Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-184	18-Aug-2022	3,750,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Glen H. Nuckolls, Ph.D.</p> <p>301-496-5745</p> <p>glen.nuckolls@nih.gov</p> <p></p> <p>Link to program URL</p> <p>18-Aug-2022 , 17-Feb-2023 , 17-Aug-2023 , 20-Feb-2024 , 19-Aug-2024 , 19-Feb-2025</p> <p>This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS expects to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.</p>			
108301	RFA-NS-22-034 -- HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-034	08-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Michael L. Oshinsky, PhD</p> <p>301-496-9964</p> <p>michael.oshinsky@nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Aug-2022 , 04-Oct-2022 , 07-Dec-2022 , 02-Feb-2023 , 07-Apr-2023 , 02-Jun-2023 , 07-Aug-2023 , 04-Oct-2023 , 07-Dec-2023 , 02-Feb-2024 , 09-Apr-2024 , 04-Jun-2024 , 07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.</p>				
111481	<p>RFA-NS-22-039 -- BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 Basic Experimental Studies with Humans Required)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-039	17-Aug-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name James Gnadt, PhD</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email BRainResOppHu@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Aug-2022 [Optional][LOI/Pre-App], 16-Sep-2022 , 16-Aug-2023 [Optional][LOI/Pre-App], 15-Sep-2023 , 14-Aug-2024 [Optional][LOI/Pre-App], 13-Sep-2024</p> <p>Synopsis This FOA will support integrated, interdisciplinary research teams that focus on examining dynamic circuit functions related to behavior, using advanced and innovative technologies. The FOA will support programs with a necessarily-synergistic, team science approach. Awards will be made for 5 years, with a possibility of one competing renewal. Applications should focus on overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should aim to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

understand these circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches and experimental design guided by specified theoretical constructs, are encouraged to employ quantitative, mechanistic and predictive models where appropriate. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise – including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. Applications will be required to manage their data and analysis methods in a framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development.

111482	RFA-NS-22-040 -- BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-040	17-Aug-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	--	---------------

Contact Name	James Gnad, PhD
Contact Telephone	301-496-9964
Contact Email	BRAINResOppHu@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Aug-2022 [Optional][LOI/Pre-App], 16-Sep-2022 , 16-Aug-2023 [Optional][LOI/Pre-App], 15-Sep-2023 , 14-Aug-2024 [Optional][LOI/Pre-App], 13-Sep-2024
Synopsis	This FOA will support integrated, interdisciplinary research teams that focus on examining dynamic circuit functions related to behavior, using advanced and innovative technologies. The FOA will support programs with a necessarily-synergistic, team science approach. Awards will be made for 5 years, with a possibility of one competing renewal. Applications should focus on overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should aim to understand these circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches and experimental design guided by specified theoretical constructs, are encouraged to employ quantitative, mechanistic and predictive models where appropriate. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise – including neurobiologists,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. Applications will be required to manage their data and analysis methods in a framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development. Applicants proposing to include human subjects in a clinical trial with invasive neural recording which meets the definition of "Basic Experiment Studies with Humans (BESH)" must apply to the companion FOA RFA-NS-22-039.</p>				
102700	Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards	National Institute of Nursing Research/NIH/DHHS	NOT-NR-21-001	08-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research.</p>				
104435	NIA Predoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F31)	National Institute on Aging/NIH/DHHS	PAR-21-218	08-Aug-2022	Not Specified
	<p>Contact Name Yuan Luo, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email yuan.luo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 08-Dec-2022 , 08-Apr-2023 , 08-Aug-2023 , 08-Dec-2023 , 08-Apr-2024 , 08-Aug-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This predoctoral fellowship program will emphasize the development of skills in data science and drug discovery and their application to various aspects</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising predoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

104399	NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-21-217	08-Aug-2022	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Jessi Perez
Contact Telephone	301-402-7739
Contact Email	perezj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2022 , 08-Dec-2022 , 08-Apr-2023 , 08-Aug-2023 , 08-Dec-2023 , 08-Apr-2024 , 08-Aug-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This postdoctoral fellowship will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising postdoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care.

108054	Notice of Special Interest (NOSI): Research on Pain, Pain Management, and Opioids in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-22-004	25-Jun-2022	Not Specified
--------	--	--------------------------------------	---------------	-------------	---------------

Contact Name	Devon Oskvig, Ph.D.
Contact Telephone	301-827-5899

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email devon.oskvig@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2022 , 08-Aug-2022 , 12-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 12-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 12-Apr-2023 , 25-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 12-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight that the National Institute on Aging (NIA) is interested in receiving grant applications focused on pain, pain management, and opioids related to aging or older adults and within NIA’s mission areas. This NOSI invites research applications that focus on improving the understanding of mechanisms underlying pain experience with aging; enhancing assessment, prevention, and management strategies for pain in older adults; and improving health equity of aging populations suffering with pain. New applications, resubmissions, competing renewals, and competing revisions to existing awards are all encouraged through this NOSI. For administrative supplements focused on pain, pain management, and opioids related to aging or older adults and within NIA’s mission areas, please see NOT-AG-22-005.</p>				
080374	Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-207	10-Aug-2022	1,000,000 USD
	<p>Contact Name Lori Ducharme, PhD</p> <p>Contact Telephone 301-451-8507</p> <p>Contact Email ducharmel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

goal, this FOA will support creative educational activities with a primary focus on Outreach. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIAAA/NIDA R25 program is to support educational activities that foster a better understanding of biomedical, behavioral, and clinical research on alcohol and other substance use disorders and their implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Outreach. Specifically, this FOA will support projects designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of alcohol and other substance use disorders and related health conditions.

101187	NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-093	08-Aug-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

104661	Notice of Special Interest (NOSI): NIDCD Health Disparities and Inequities Research	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-003	08-Aug-2022	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Kelly King, Au.D, Ph.D.
Contact Telephone	301-402-3458
Contact Email	kingke@nidcd.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Apr-2024 , 07-May-2024			
	Synopsis	This Notice of Special Interest (NOSI) encourages applications that advance the understanding or reduce the impact of health disparities and inequities in communication disorders among racial/ethnic minority and other underrepresented populations. Applications that address the influence or reduction of racism or discrimination in causing or sustaining health disparities and inequities are also encouraged. The research must address one or more of the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.			
095406	NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-221	15-Aug-2022	3,500,000 USD
	Contact Name	Redonna Chandler, PhD			
	Contact Telephone	301-402-1919			
	Contact Email	redonna.chandler@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			
	Synopsis	The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term “avant-garde” refers to highly innovative ideas and/or approaches that have the potential to be transformative. Applications responding to this FOA must propose research that is substantially different from what is currently being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html . The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV/AIDS for PWUD; creative, new strategies to prevent HIV transmission in high-risk drug using populations; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches to eradicating HIV and improving the lives of PWUD living with HIV in general.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
097172	NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-267	26-Aug-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Kevin Walton, Ph.D.</p> <p>Contact Telephone 301-8270-5980</p> <p>Contact Email Kevin.Walton@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Aug-2022 [Optional][LOI/Pre-App], 26-Sep-2022 , 17-Nov-2022</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications to establish Core Centers of Excellence. Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program. This FOA will use the NIH P30 award mechanism.</p>				
099069	New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-273	11-Aug-2022	Not Specified
	<p>Contact Name Minnjuan Flournoy Floyd, PhD</p> <p>Contact Telephone 301-827-6474</p> <p>Contact Email Minnjuan.flournoyfloyd@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Aug-2022 , 18-Nov-2022 , 11-Aug-2023</p> <p>Synopsis The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.			
108983	RFA-DA-23-003 -- Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-003	03-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Amy C. Lossie, PhD			
	Contact Telephone	301-827-6092			
	Contact Email	lossieac@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jul-2022 [Optional][LOI/Pre-App], 03-Aug-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support research examining the potential contributions of mobile DNA elements and addictive substances in HIV integration, reservoir formation, and maintenance in the brain. NIDA is specifically interested in studies exploring the contributions of molecular, genetic, and epigenetic factors in HIV integration, reservoir formation, and maintenance in microglia and/or the brain in the context of addiction.			
109415	RFA-DA-23-006 -- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-006	12-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Richard A. Jenkins PhD			
	Contact Telephone	301-443-1923			
	Contact Email	jenkinsri@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022 , 12-Jul-2023 [Optional][LOI/Pre-App], 11-Aug-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) is to support development and testing of intervention models that demonstrate how Syringe Service Programs (SSPs) can support expanded implementation of evidence-based HIV services. This research should address the needs and resources of SSP settings (e.g., standalone, CBO/ASO, FQHC, health dept-based) and delivery models (e.g., fixed site, mobile) that partner in the research, as well as what is feasible given the local or			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		regional organization of substance use and HIV services. SSPs have a history of strong ties to their communities and involvement by people who inject drugs (PWID) and allies. Applications should demonstrate substantive involvement of the community in all phases of the proposed projects and establish community advisory boards or other linkages to the community where they do not currently exist.			
109419	RFA-DA-23-007 -- Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-007	12-Jul-2022 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Richard A. Jenkins PhD 301-443-1923 jenkinsri@mail.nih.gov Link to program URL 12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022 , 12-Jul-2023 [Optional][LOI/Pre-App], 11-Aug-2023 This Funding Opportunity Announcement (FOA) supports pilot development and testing of pilot intervention models to demonstrate how syringe service programs (SSPs) can support expanded implementation of evidence-based HIV services. This research should address the needs and resources of SSP settings (e.g., standalone, CBO/ASO, FQHC, health dept-based) and delivery models (e.g., fixed site, mobile) that partner in the research, as well as what is feasible given the local or regional organization of substance use and HIV services. SSPs have a history of strong ties to their communities and involvement by people who inject drugs (PWID) and allies. Applications should demonstrate substantive involvement of the community in all phases of the proposed projects and establish community advisory boards or other linkages to the community where they do not currently exist.			
099073	New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-274	11-Aug-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Minnjuan Flournoy Floyd, PhD 301-827-6474 Minnjuan.flournoyfloyd@nih.gov Link to program URL 11-Aug-2022 , 18-Nov-2022 , 11-Aug-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This funding opportunity announcement will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.			
095411	Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-224	15-Aug-2022	1,500,000 USD
	Contact Name	Redonna Chandler, Ph.D.			
	Contact Telephone	301-402-1919			
	Contact Email	rchandle@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			
	Synopsis	Avenir means future in French, and the Avenir Award Program for research on Substance Use Disorders (SUD) and HIV/AIDS looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html . The Avenir Award Program will support creative individuals who wish to pursue innovative research at the nexus of SUD and HIV/AIDS. The purpose of this program is to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, optimizing therapies for HIV and SUD, reducing the impact of comorbid conditions, and ultimately, eradicating HIV. Applications responding to this FOA must clearly describe the intersection of substance use disorders with HIV/AIDS.			
103052	Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-208	10-Aug-2022	275,000 USD
	Contact Name	Amy C. Lossie, Ph.D.			
	Contact Telephone	301-827-6092			
	Contact Email	lossieac@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Aug-2022 , 08-Mar-2023 , 10-Aug-2023 , 08-Mar-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.</p>			
106312	RFA-DA-22-040 -- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-040	15-Aug-2022	Not Specified
	Contact Name	Richard A. Jenkins, Ph.D.			
	Contact Telephone	301-443-1923			
	Contact Email	jenkinsri@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022 , 15-Feb-2023 , 15-Aug-2023 , 15-Feb-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.</p>			
108341	Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-038	05-Aug-2022	Not Specified
	Contact Name	Marsha F. Lopez, Ph.D., M.H.S.			
	Contact Telephone	301-443-6504			
	Contact Email	marsha.lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Aug-2022 , 15-Nov-2022 , 07-Mar-2023 , 09-Aug-2023 , 15-Nov-2023 , 04-Mar-2024 , 05-Aug-2024 , 15-Nov-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.</p>				
108340	RFA-DA-22-037 -- Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-037	05-Aug-2022	Not Specified
	<p>Contact Name Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email marsha.lopez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Aug-2022 , 15-Nov-2022 , 07-Mar-2023 , 09-Aug-2023 , 15-Nov-2023 , 04-Mar-2024 , 05-Aug-2024 , 15-Nov-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.</p>				
101983	RFA-DA-22-004 -- Exploratory Studies to Investigate Mechanisms of HIV Infection Replication, Latency, and/or Pathogenesis in the	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-004	10-Aug-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Context of Substance Use Disorders \(R61/R33 - Clinical Trial Not Allowed\)](#)

Contact Name	Shang-Yi Anne Tsai, Ph.D.
Contact Telephone	301-827-5842
Contact Email	stsai@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Aug-2022
Synopsis	The purpose of this FOA is to support exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. The FOA aims to promote research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.

111016	Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-22-182	10-Aug-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Will M. Aklin, Ph.D.
Contact Telephone	301-827-5909
Contact Email	aklinwm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Aug-2022 , 21-Mar-2023 , 10-Aug-2023 , 21-Mar-2024 , 09-Aug-2024 , 21-Mar-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II (“Efficacy”) research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III (“Efficacy in Real-World”) research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

111018	Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-22-183	10-Aug-2022	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Will M. Aklin, Ph.D.
Contact Telephone	301-827-5909
Contact Email	aklinwm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Aug-2022 , 21-Mar-2023 , 10-Aug-2023 , 21-Mar-2024 , 09-Aug-2024 , 21-Mar-2025

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II (“Efficacy”) research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III (“Efficacy in Real-World”) research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

109761	RFA-DA-23-010 -- Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-010	15-Aug-2022	450,000 USD
--------	---	---	---------------	-------------	-------------

Contact Name | Carrie Mulford
 Contact Telephone | 301-827-6473
 Contact Email | Carrie.Mulford@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 15-Aug-2022

Synopsis | This Funding Opportunity Announcement (FOA) encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials examining strategies to address social connectedness and/or loneliness in order to prevent or treat SUDs or enhance recovery. The goal of this FOA is to develop user-centered interventions addressing social connectedness and loneliness in the context of substance use that are effective, practical, cost-effective, scalable, and sustainable.

109760	RFA-DA-23-009 -- Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-009	15-Aug-2022	275,000 USD
--------	--	---	---------------	-------------	-------------

Contact Name | Carrie Mulford
 Contact Telephone | 301-827-6473
 Contact Email | Carrie.Mulford@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Aug-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages exploratory and developmental research to better understand the role of social connectedness and/or loneliness in prevention, treatment and recovery from substance use disorders (SUDs). Research may use a variety of approaches, including leveraging existing data sources, survey research, social network analysis, new methods development, feasibility research, etc. Outcomes of interest include any of the following: substance use initiation, escalation, SUD diagnosis, connection to treatment, and engagement or retention in treatment or recovery.</p>				
096665	NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-249	02-Aug-2022	2,500,000 USD
	<p>Contact Name Aria Davis Crump, Sc.D.</p> <p>Contact Telephone 301-435-0881</p> <p>Contact Email acrump@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Aug-2022 , 15-Nov-2022 , 01-Mar-2023 , 02-Aug-2023 , 15-Nov-2023</p> <p>Synopsis This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research. For this FOA, clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral level social workers, pharmacists, and behavioral scientists. Scholars are expected to be supported for 3-5 years on consecutive 12-month appointments. Candidates selected for support as scholars must hold a doctorate and commit a minimum of 9 person months (equivalent to 75% of full-time professional effort) to conducting clinical research and career development activities associated with the proposed program This FOA allows appointment of scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109944	RFA-DA-23-014 -- Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-014	11-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sam Ananthan, Ph.D.</p> <p>Contact Telephone 301-435-2199</p> <p>Contact Email sam.ananthan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022</p> <p>Synopsis Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field.</p>				
110056	RFA-DA-23-021 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-021	16-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Leonardo Angelone, PhD</p> <p>Contact Telephone 301-827-5946</p> <p>Contact Email leonardo.angelone@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Jul-2022 [Optional][LOI/Pre-App], 15-Aug-2022 , 15-Jan-2023 [Optional][LOI/Pre-App], 14-Feb-2023 , 16-Jul-2023 [Optional][LOI/Pre-App], 15-Aug-2023 , 15-Jan-2024 [Optional][LOI/Pre-App], 14-Feb-2024 , 14-Jul-2024 [Optional][LOI/Pre-App], 13-Aug-2024 , 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

110733	RFA-DA-23-012 -- Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-012	12-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Da-Yu Wu, PhD
Contact Telephone	301-435-4649
Contact Email	wudy@nida.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022 , 12-Jul-2023 [Optional][LOI/Pre-App], 11-Aug-2023
Synopsis	This Funding Opportunity Announcement (FOA) supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology.

097374	Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-279	10-Aug-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Kevin Walton, Ph.D.
Contact Telephone	301-827-5980
Contact Email	kevin.walton@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Aug-2022 , 14-Dec-2022 , 10-Aug-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must address both UG3 and UH3 phases.</p>				
110736	RFA-DA-23-040 -- Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-040	10-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Richard A. Jenkins, PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jul-2022 [Optional][LOI/Pre-App], 10-Aug-2022</p> <p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support a coordinating center (CC), which will coordinate research efforts across the NIDA funded longitudinal cohorts that address emerging and high priority research on HIV/AIDS in the context of substance use and substance use disorders (SUD). The CC will serve as 1) a national data and specimen resource that harmonizes and collects data and biological samples from the NIDA cohorts and affiliated studies, and enables additional research efforts through virtual repositories; 2) a facilitator of current and future research at the intersection of HIV and substance use and SUD; and 3) the central hub for organizing and enabling communication within and outside the NIDA cohort studies program, including annual meetings, advisory and scientific oversight committees.</p>				
102968	Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-183	04-Aug-2022	Not Specified
	<p>Contact Name Will M. Aklin, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-5909</p> <p>Contact Email aklinwm@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Aug-2022 , 06-Dec-2022 , 06-Apr-2023 , 04-Aug-2023 , 06-Dec-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must address both UG3 and UH3 phases.</p>				
109183	<p>Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders</p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-056	04-Aug-2022	Not Specified
	<p>Contact Name Will M.Aklin, Ph.D.</p> <p>Contact Telephone 301-869-1665</p> <p>Contact Email aklinwm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Aug-2022 , 06-Dec-2022 , 06-Apr-2023 , 04-Aug-2023 , 06-Dec-2023</p> <p>Synopsis There is an urgent public health need for the expansion of available therapeutic options for individuals with Opioid and Polysubstance Use Disorders as the efficacy of many treatments decrease over the long-term. The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments. In response to this public health need, the HEAL Initiative will consider funding scientifically meritorious applications that focus on evaluating the safety and/or the efficacy of digital therapeutics to opioid</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

use disorders alone or in combination with other Substance Use Disorders (SUD) that are submitted in response to PAR-21-183.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110304	RFA-DA-23-002 -- Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-002	11-Aug-2022	Not Specified

Contact Name	Minnjuan W. Flournoy Floyd, PhD, MPH, MBA
Contact Telephone	301-827-6474
Contact Email	Minnjuan.flournoyfloyd@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-Aug-2022
Synopsis	The purpose of the Funding Opportunity Announcement (FOA) is to support research that addresses limitations in understanding how to ensure all people who use drugs (PWUD) and are at risk for, or living with HIV have rapid access to high quality substance use disorder (SUD) treatment and HIV care services, including Pre-exposure prophylaxis (PrEP). This FOA is intended to support research that develops and tests interventions at the system, organization, provider, and/or social determinants of health levels to reduce the time between HIV testing and/or diagnosis and linkage to appropriate HIV care for PWUD. In addition to rapid HIV care, projects supported through this FOA should also address the identification of SUD service needs and rapid linkage to appropriate services. Because access to care is also impacted by sex, gender identity, sexual orientation, and race/ethnicity structural and systems-level interventions paying special attention to equity will be given priority consideration for funding.

106250	NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-320	10-Aug-2022	1,750,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Aria Davis Crump, Sc.D.
Contact Telephone	301-435-0881
Contact Email	acrump@nida.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022 , 15-Nov-2022 , 15-Mar-2023 , 10-Aug-2023 , 15-Nov-2023 , 15-Mar-2024 , 09-Aug-2024</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences. The proposed research education programs must include both courses for skills development and research experiences with primary emphasis on research experiences. Proposed courses should be developed in conjunction with and support research experiences to enhance skills development.</p>				
111871	RFA-DA-23-052 -- Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-052	10-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Richard A. Jenkins, PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Jul-2022 [Optional][LOI/Pre-App], 10-Aug-2022</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) seeks applications for a coordinating center (CC), which will coordinate research efforts across the NIDA funded longitudinal cohorts that address emerging and high priority research on HIV/AIDS in the context of substance use and substance use disorders (SUD). The CC will serve as 1) a national data and specimen resource that harmonizes and collects data and biological samples from the NIDA cohorts and affiliated studies, and enables additional research efforts through virtual repositories; 2) a facilitator of current and future research at the intersection of HIV and substance use and SUD; and 3) the central hub for organizing and enabling communication within and outside the NIDA cohort studies program, including annual meetings, advisory and scientific oversight committees.</p>				
104862	Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	25-Jun-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Yu (Woody) Lin</p> <p>Contact Telephone 301-435-1318</p> <p>Contact Email ylin1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jun-2022 , 15-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.</p>				
107619	Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002	10-Aug-2022	Not Specified

	<p>Contact Name Kiran Vemuri, Ph.D.</p> <p>Contact Telephone 301-435-4446</p> <p>Contact Email kiran.vemuri@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 08-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 12-Feb-2025</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	<p>The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.</p>				
105016	RFA-ES-21-006 -- CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-ES-21-006	22-Aug-2022 [Optional][LOI/Pre-App]	Not Specified	
	Contact Name	Srikanth Nadadur, Ph.D				
	Contact Telephone	984-287-3296				
	Contact Email	nadadurs@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-Aug-2022 [Optional][LOI/Pre-App], 21-Sep-2022 , 21-Aug-2023 [Optional][LOI/Pre-App], 20-Sep-2023				
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the lungs and eyes. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).</p>				
108531	RFA-TR-22-013 -- Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-TR-22-013	23-Jul-2022 [Optional][LOI/Pre-App]	1,500,000 USD	
	Contact Name	Steven Pittenger, Ph.D				
	Contact Telephone	301-827-5810				
	Contact Email	steven.pittenger@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 23-Jul-2022 [Optional][LOI/Pre-App], 22-Aug-2022 , 22-Apr-2023 [Optional][LOI/Pre-App], 22-May-2023</p> <p>Synopsis The participating NIH Institutes and Centers are issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis. The Helping End Addiction Long-Term (HEAL) New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research related to pain, opioid use disorder (OUD), and/or overdose (OD). Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged.</p>				
100480	<p>Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)</p>	National Institutes of Health/DHHS	PAR-20-236	10-Aug-2022	1,250,000 USD
	<p>Contact Name Albert Avila, PhD</p> <p>Contact Telephone 301-496-8804</p> <p>Contact Email aavila@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022 , 15-Nov-2022 , 15-Mar-2023 , 10-Aug-2023 , 15-Nov-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development</p>				
109825	<p>RFA-DA-23-004 -- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 - Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-DA-23-004	12-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name John Satterlee, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-1020</p> <p>Contact Email satterleej@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jul-2022 [Optional][LOI/Pre-App], 11-Aug-2022</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) seeks applications that support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine, methamphetamine, or cannabinoid use disorder</p>				
102724	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-163	09-Aug-2022	Not Specified
	<p>Contact Name Ann-Marie Broome, Ph.D. MBA</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email ann-marie.broome@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Aug-2022 , 07-Sep-2022 , 09-Feb-2023 , 07-May-2023 , 09-Aug-2023 , 07-Sep-2023 , 09-Feb-2024 , 07-May-2024</p> <p>Synopsis The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.</p>				
102904	Notice of Special Interest (NOSI): Conferences and Scientific Meetings Aimed at Supporting the National Eye Institute's Audacious Goals Initiative	National Institutes of Health/DHHS	NOT-EY-21-009	12-Aug-2022	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Houmam Araj, PhD</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email arajh@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Aug-2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Jan-2023 , 12-Apr-2023 , 07-May-2023 , 12-Aug-2023 , 07-Sep-2023 , 12-Dec-2023 , 07-Jan-2024 , 12-Apr-2024 , 07-May-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) is to solicit applications to support conferences, symposia, and workshops aimed at supporting the National Eye Institute's (NEI) Audacious Goals Initiative.</p>				
100374	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)	National Institutes of Health/DHHS	PA-21-051	08-Aug-2022	Not Specified

	<p>Contact Name </p> <p>Contact Telephone </p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements, and Staff Contacts website (https://grants.nih.gov/grants/guide/contacts/parent_F30b.html) ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>					
100542	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)	National Institutes of Health/DHHS	PA-21-052	08-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow candidates to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
100438	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-21-050	08-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
100436	<p>Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)</p>	National Institutes of Health/DHHS	PA-21-049	08-Aug-2022	Not Specified

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

100434	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)	National Institutes of Health/DHHS	PA-21-048	08-Aug-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-945-7573
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023
Synopsis	The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

100399	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	National Institutes of Health/DHHS	PA-21-047	08-Aug-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.			
102106	NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-21-151	12-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Aug-2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Jan-2023 , 12-Apr-2023 , 07-May-2023 , 12-Aug-2023 , 07-Sep-2023 , 12-Dec-2023 , 07-Jan-2024			
	Synopsis	The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.			
111041	RFA-AI-22-037 -- Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-22-037	15-Aug-2022 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Melody Mills, PhD			
	Contact Telephone	240-507-9576			
	Contact Email	millsm@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022 [Optional][LOI/Pre-App], 14-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications focused on advancing development of vaccine candidates against Enterotoxigenic Escherichia coli (ETEC), Salmonella enterica serotype Paratyphi A, and two Shigella species, Shigella flexneri and Shigella sonnei.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
089925	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-111	09-Aug-2022	Not Specified
	<p>Contact Name Charles Cywin, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email charles.cywin@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Aug-2022 , 07-Sep-2022 , 09-Feb-2023 , 07-May-2023 , 09-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.</p>				
089937	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-122	09-Aug-2022	Not Specified
	<p>Contact Name Charles Cywin, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email charles.cywin@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Aug-2022 , 07-Sep-2022 , 09-Feb-2023 , 07-May-2023 , 09-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.</p>				
110100	RFA-AI-22-025 -- Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AI-22-025	04-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Diane Lawrence, Ph.D.</p> <p>Contact Telephone 240-627-3202</p> <p>Contact Email lawrencedi@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Jul-2022 [Optional][LOI/Pre-App], 03-Aug-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic research to define cellular and molecular mechanisms within persistent HIV reservoir cells that promote survival and resistance to virus-induced and immune-mediated cell death, and to identify novel therapeutic targets that could sensitize HIV-infected cells to eradication strategies.</p>				
108544	Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-22-058	01-Aug-2022	Not Specified
	Contact Name Steven T. Pittenger, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-827-5810				
Contact Email	Steven.Pittenger@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Aug-2022 , 01-May-2023				
Synopsis	<p>NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis. This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates – associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development. The development of novel treatments for pain, addiction, and overdose is a vital component to address the ongoing opioid epidemic. This development will be most effective if performed by scientists with experience in translational science. Translation is defined as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioral changes, with translational science representing the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process (https://ncats.nih.gov/translation). Traditional academic training provides deep knowledge of a relatively narrow scientific discipline. While domain expertise is an important characteristic of a proficient translational scientist, a comprehensive understanding of the stages of therapeutic development is also necessary. For many scientists, acquiring needed expertise through participatory involvement in the various fields that are required to compile an investigational new drug (IND), investigational device exemption (IDE), or new drug application (NDA) is extraordinarily difficult given the diversity of these domains. This FOA is designed for early- and mid- career scientists with pain or opioid abuse expertise interested in receiving hands-on experience in translation at an industry laboratory, or an academic or government research center performing therapeutic development activities. The selected research environment should have the requisite capabilities and employ scientists and staff with expertise across the entire translational space for small molecule, biologic, or device development. Areas of requisite capabilities and expertise include, but are not limited to: assay development, high-throughput screening technology, medicinal chemistry, analytical chemistry, advanced informatics, chemistry, manufacturing and controls (CMC), formulation, and toxicology needs assessments, risk assessment, benchtop models, in vitro models, in vivo models, cadaver testing, biocompatibility, shelf-life/stability, sterilization, leachables/extractables, electromagnetic compatibility, quality and data management systems, Phase I, II, III clinical trials, FDA regulatory requirements, human subjects protections, and data and safety monitoring. Potential instructional sites included: academic laboratories, pharmaceutical companies, medical</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>device companies, biotechnologies companies, and non-profit research organizations. translating small molecules, biologics or devices. For more information, please see Questions and Answers at https://ncats.nih.gov/heal/funding/application-information-par-22-058. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>			
110096	Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-22-132	27-Jul-2022	Not Specified
	<p>Contact Name Brad Newsome, Ph.D.</p> <p>Contact Telephone 301-480-8389</p> <p>Contact Email brad.newsome@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Jul-2022 , 10-Aug-2022</p> <p>Synopsis The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (AI/AN) Tribal Nation populations in the United States. This Funding Opportunity Announcement (FOA) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. Specifically, this FOA invites applications that propose interventions targeting critical life stages (e.g., infancy, childhood, adolescence, pregnancy, older adults) and key transitions between life stages to reduce health risk and/or enhance positive health and lifestyle behaviors. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations"). Applications will be accepted from US and World Bank-defined LMIC institutions only.</p>				
109943	RFA-CA-22-017 -- Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-CA-22-017	23-Jul-2022 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Monique Pond, Ph.D.</p> <p>Contact Telephone 240-276-5014</p> <p>Contact Email monique.pond@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jul-2022 [Optional][LOI/Pre-App], 22-Aug-2022</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.</p>				
110793	RFA-RM-22-021 -- NIH Director's Early Independence Awards (DP5 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-RM-22-021	02-Aug-2022 [Optional][LOI/Pre-App]	1,250,000 USD
	<p>Contact Name Becky Miller, Ph.D.</p> <p>Contact Telephone 301-594-9979</p> <p>Contact Email earlyindependence@od.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Aug-2022 [Optional][LOI/Pre-App], 02-Sep-2022</p> <p>Synopsis The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<https://commonfund.nih.gov>) through the Office of the NIH Director, Office of Strategic Coordination (<https://dpcpsi.nih.gov>). All NIH Institutes and Centers participate in Common Fund initiatives. Grants management of the awards will be administered by the National Institute of Dental and Craniofacial Research (<http://www.nidcr.nih.gov>) on behalf of the NIH.

103723	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-233	09-Aug-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Ann-Marie Broome PhD MBA
Contact Telephone	301-496-1779
Contact Email	ann-marie.broome@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Aug-2022 , 05-Sep-2022 , 09-Feb-2023 , 05-Apr-2023 , 09-Aug-2023 , 05-Sep-2023 , 09-Feb-2024 , 05-Apr-2024
Synopsis	The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
099811	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-300	10-Aug-2022	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Zhaoxia Ren, M.D., Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-9340</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>zren@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>10-Aug-2022 , 09-Dec-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.</td> </tr> </table>					Contact Name	Zhaoxia Ren, M.D., Ph.D.	Contact Telephone	301-402-9340	Contact Email	zren@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	10-Aug-2022 , 09-Dec-2022	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.
Contact Name	Zhaoxia Ren, M.D., Ph.D.																		
Contact Telephone	301-402-9340																		
Contact Email	zren@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	10-Aug-2022 , 09-Dec-2022																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.																		
099856	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-299	10-Aug-2022	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Zhaoxia Ren, M.D., Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-9340</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>zren@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>10-Aug-2022 , 09-Dec-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.</td> </tr> </table>					Contact Name	Zhaoxia Ren, M.D., Ph.D.	Contact Telephone	301-402-9340	Contact Email	zren@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	10-Aug-2022 , 09-Dec-2022	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.
Contact Name	Zhaoxia Ren, M.D., Ph.D.																		
Contact Telephone	301-402-9340																		
Contact Email	zren@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	10-Aug-2022 , 09-Dec-2022																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.																		
111260	Notice of Special Interest (NOSI): Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship Awards to Support Training in Research Related to Down Syndrome as Part of the INCLUDE Project	National Institutes of Health/DHHS	NOT-OD-22-126	08-Aug-2022	Not Specified														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Charlene Schramm, PhD</p> <p>Contact Telephone 301-402-3793</p> <p>Contact Email schrammc@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024 , 08-Apr-2024</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of trainees aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS. Investigators early in their careers (e.g., predoctoral candidates) as well as those with advanced degrees (e.g., PhD, MD) may benefit from mentorship from established investigators and professionals in the DS research community in basic science fields as well as clinical and translational arenas.</p>				
110442	<p>RFA-MD-22-009 -- Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 - Clinical Trial Required)</p>	National Institutes of Health/DHHS	RFA-MD-22-009	15-Jul-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Rick Berzon, DrPH, PA</p> <p>Contact Telephone 301-594-8949</p> <p>Contact Email Rick.berzon@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jul-2022 [Optional][LOI/Pre-App], 15-Aug-2022</p> <p>Synopsis This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110503	RFA-AI-22-024 -- Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-AI-22-024	04-Jul-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Gerald B. Sharp, Dr.P.H.</p> <p>Contact Telephone 240-627-3217</p> <p>Contact Email GSharp@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Jul-2022 [Optional][LOI/Pre-App], 03-Aug-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to enroll large, digitally-maintained cohorts of people with HIV-1 (PWH) in the United States who are not adequately virally suppressed. Applicants will need to employ sampling strategies that ensure meaningful enrollment of participants who report prior gaps in HIV care engagement and/or lack of sustained viral suppression (VS). The goal is to follow the research cohort over time to prospectively investigate trajectories of HIV care engagement and viral suppression, as well as the temporal antecedents and multilevel factors that drive changes in care engagement, antiretroviral adherence, and viral suppression. Researchers may test strategies for improved methods of screening, enrollment, and retention of cohort participants. Projects should seek to inform future interventions to promote sustained engagement in HIV care and sustained HIV viral suppression, and additionally have the option of testing digitally-delivered interventions toward that end.</p>				
102286	Global Infectious Disease Research Training Program [D43 Clinical Trial Optional]	National Institutes of Health/DHHS	PAR-21-120	03-Aug-2022	Not Specified
	<p>Contact Name Barbara Sina Ph.D.</p> <p>Contact Telephone 301-402-9467</p> <p>Contact Email sinab@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Aug-2022 , 03-Aug-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research not including HIV/AIDS. FIC will support research-training programs that focus on major endemic or life-threatening</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and professional development.

111443	RFA-NS-22-041 -- BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	RFA-NS-22-041	23-Aug-2022 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	--	---------------

Contact Name	James Gnadt, Ph.D.
Contact Telephone	301-496-9964
Contact Email	BRAINResOppHu@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Aug-2022 [Optional][LOI/Pre-App], 23-Sep-2022 , 22-Aug-2023 [Optional][LOI/Pre-App], 22-Sep-2023 , 21-Aug-2024 [Optional][LOI/Pre-App], 21-Sep-2024
Synopsis	<p>Invasive surgical procedures offer the opportunity for unique intracranial interventions such as the ability to record and stimulate intracranially within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and need to be aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to the brain from invasive surgical procedures. Projects should employ approaches guided by specified theoretical constructs and by quantitative, mechanistic models where appropriate. Awardees will join a consortium work group, coordinated by the NIH, to identify consensus standards of practice, including neuroethical considerations, to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
111616	Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project	National Institutes of Health/DHHS	NOT-OD-22-123	26-Aug-2022	Not Specified
	<p>Contact Name Charlene Schramm, PhD</p> <p>Contact Telephone 301-402-3739</p> <p>Contact Email schrammc@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>				
111641	Notice of Special Interest (NOSI): Climate Change and Health	National Institutes of Health/DHHS	NOT-ES-22-006	08-Jul-2022	Not Specified
	<p>Contact Name Claudia L. Thompson</p> <p>Contact Telephone 984-287-3330</p> <p>Contact Email thomps01@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Jul-2022 , 13-Jul-2022 , 01-Aug-2022 , 03-Aug-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 19-Oct-2022 , 03-Nov-2022 , 14-Nov-2022 , 15-Nov-2022 , 08-Dec-2022 , 09-Dec-2022 , 20-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 21-Feb-2023 , 08-Mar-2023 , 10-Mar-2023 , 13-Mar-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 19-Jun-2023 , 10-Jul-2023 , 13-Jul-2023 , 03-Aug-2023 , 08-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 19-Oct-2023 , 03-Nov-2023 , 13-Nov-2023 , 15-Nov-2023 , 08-Dec-2023 , 11-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>2024 , 16-Feb-2024 , 20-Feb-2024 , 11-Mar-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 19-Jun-2024 , 09-Jul-2024 , 15-Jul-2024 , 08-Aug-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 21-Oct-2024 , 12-Nov-2024 , 15-Nov-2024 , 08-Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 19-Feb-2025 , 08-Apr-2025 , 07-May-2025</p> <p>The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.</p>				
102080	<p>Notice of Special Interest (NOSI): Availability of Administrative Supplements for BRAIN Initiative Awardees to Support Resource Dissemination</p>	National Institutes of Health/DHHS	NOT-NS-21-014	31-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Dr. Kari Ashmont</p> <p>301-496-1779</p> <p>Kari.Ashmont@nih.gov</p> <p></p> <p>Link to program URL</p> <p>31-Aug-2022 , 30-Nov-2022 , 28-Feb-2023</p> <p>This Notice of Special Interest (NOSI) announces the availability of administrative supplements to support the dissemination of promising technologies and resources generated from active Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative awards, to foster collaborations between innovators and new end-user laboratories, and ultimately integrate such innovations into neuroscience research practice.</p>			
102689	<p>RFA-OD-21-003 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-OD-21-003	08-Aug-2022	275,000 USD
	<p>Contact Name</p>	<p>Rachel Grana Mayne, PhD</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-5899</p> <p>Contact Email granar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).</p>				
100652	<p>Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)</p>	National Institutes of Health/DHHS	PAR-21-039	26-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</p> <p>Synopsis The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate ‘Clinical Trial Not Allowed’ FOA .</p>																		
100648	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-038	26-Aug-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-945-7573</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>GrantsInfo@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.</td> </tr> </table>					Contact Name		Contact Telephone	301-945-7573	Contact Email	GrantsInfo@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023	Synopsis	The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.
Contact Name																			
Contact Telephone	301-945-7573																		
Contact Email	GrantsInfo@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023																		
Synopsis	The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.																		
111545	FCO-- AMENDMENT -- Research Opportunity Announcement (ROA): NIH All of Us Engagement, Communications, and Enrollment Partnerships	National Institutes of Health/DHHS	OTA-22-006	31-Aug-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> </table>					Contact Name		Contact Telephone											
Contact Name																			
Contact Telephone																			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	AOU-ROA@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	31-Aug-2022 , 30-Nov-2022 , 28-Feb-2023 , 31-May-2023 , 31-Aug-2023 , 30-Nov-2023 , 29-Feb-2024 , 31-May-2024 , 30-Aug-2024 , 29-Nov-2024 , 28-Feb-2025 , 23-May-2025
Synopsis	<p>Research Opportunity Announcement (ROA) Title: All of Us Engagement, Communications, and Enrollment Partnerships ROA Number: OTA-22-006 ROA Open Period: May 26, 2022 to May 23, 2025 (Note: open period includes multiple white paper deadlines) Overview: The All of Us Research Program, within the Office of the Director (OD) at the National Institutes of Health (NIH), has issued a research opportunity announcement to solicit white papers supporting various Areas of Interest (AOIs). A ROA is a method of solicitation that announces the anticipated availability of Other Transactions (OT) awards, a special type of legal instrument other than contracts, grants, or cooperative agreements. Purpose: The All of Us Research Program is a historic effort to gather data from at least 1 million people, with the goal of accelerating health research and medical breakthroughs, and enabling individualized prevention, treatment, and care. The program is creating a national research resource to inform thousands of studies, covering a wide variety of health conditions. Researchers will use data from the program to learn more about how individual differences in lifestyle, environment, and biological makeup can influence health and disease. The purpose of this announcement is to fund organizations who can help All of Us build its cohort of volunteers who reflect the rich diversity of the United States and are actively engaged as partners. These funded organizations will help design and implement strategies to raise awareness of the program through community and health care provider organizations, drive increased enrollment of participants, foster regular communication with participants, and engage the research community to use the data being gathered. Award Project Duration: Award periods are anticipated to be up to five (5) years but may be shortened or extended as needed. Pre-Submission Webinar: A webinar will be conducted on June 27, 2022 at [Time TBD]. Registration information will be posted here once it is available. White Paper Deadlines: This ROA will remain open for three (3) years from its issue date, unless otherwise updated via an amendment, and includes multiple white paper (WP) submission deadlines. All WP deadline times are 3:00 PM Eastern Time: Calendar Year 2022 WP Deadlines August 31, 2022 November 30, 2022 Calendar Year 2023 WP Deadlines February 28, 2023 May 31, 2023 August 31, 2023 November 30, 2023 Calendar Year 2024 WP Deadlines February 29, 2024 May 31, 2024 August 30, 2024 November 29, 2024 Calendar Year 2025 WP Deadlines February 28, 2025 May 23, 2025 Documents and Related Links: The full ROA package is attached in the 'Attachments/Links' section. Potential offerors are encouraged to carefully review the announcement before submitting questions and/or preparing a white paper submission. A link to the All of Us Research Program webpage has been provided for additional information about our program.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
111738	RFA-NS-22-051 -- Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-22-051	11-Jul-2022 [Optional][LOI/Pre-App]	15,000,000 USD
	<p>Contact Name Argenia Doss, Ph.D.</p> <p>Contact Telephone 301-827-1373</p> <p>Contact Email argenia.doss@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jul-2022 [Optional][LOI/Pre-App], 10-Aug-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications for a Data Management and Coordinating Center (DMCC) to provide infrastructure, data management, and clinical research support for a new network of clinical sites that provide diagnostic services for undiagnosed diseases. The new Network is intended to sustain some of the key research activities currently performed by the Undiagnosed Diseases Network (UDN), an NIH Common Fund program that was established in 2013 and will sunset in 2023. The DMCC will coordinate clinical sites that apply to join the new Network beginning in FY2023 as Diagnostic Centers of Excellence (DCoEs) through a related Resource Access Program (X01) or other NIH funding mechanisms. The DMCC will support the DCoEs and the NIH intramural Undiagnosed Diseases Program (UDP) by coordinating trans-network research activities, with services managed across three Cores: 1) Administrative Core; 2) Data Management Core, and 3) Clinical Research Support Core.</p>				
111737	RFA-ES-22-003 -- Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 – Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-ES-22-003	25-Jul-2022 [Optional][LOI/Pre-App]	6,750,000 USD
	<p>Contact Name Abee L. Boyles, PhD</p> <p>Contact Telephone 984-287-3241</p> <p>Contact Email abee.boyles@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jul-2022 [Optional][LOI/Pre-App], 25-Aug-2022</p> <p>Synopsis The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) are</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>leading an NIH-wide Climate Change and Health (CCH) Initiative with the goals of reducing the health threats posed by climate change across the lifespan, including by improving the health of people who are at increased risk from or disparately affected by climate change impacts, and to build health resilience among individuals, communities, Tribal Nations, and nations around the world, thereby addressing health equity. This Funding Opportunity Announcement (FOA) solicits applications from eligible institutions to develop a Research Coordinating Center (RCC) to support the development of an NIH CCH Community of Practice (COP) by managing and supporting current CCH research and capacity building efforts and supporting the expansion of the COP in the long term.</p>				
102690	RFA-OD-21-004 -- Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-21-004	08-Aug-2022	275,000 USD
	Contact Name	Rachel Grana Mayne, PhD			
	Contact Telephone	240-276-5899			
	Contact Email	granar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Aug-2022 , 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105957	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-305	11-Jul-2022	Not Specified
	<p>Contact Name Mary Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jul-2022 , 09-Aug-2022 , 09-Sep-2022 , 07-Oct-2022 , 09-Nov-2022 , 09-Dec-2022 , 10-Jan-2023 , 09-Feb-2023 , 09-Mar-2023 , 11-Apr-2023 , 09-May-2023 , 09-Jun-2023 , 11-Jul-2023 , 09-Aug-2023 , 08-Sep-2023 , 09-Oct-2023 , 10-Oct-2023 , 11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</p>				
107449	Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings	National Institutes of Health/DHHS	NOT-DA-21-060	11-Aug-2022	Not Specified
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	11-Aug-2022 , 15-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 18-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 11-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The National Institute on Drug Abuse (NIDA) recognizes that stigma is pervasive in clinic, social service and other settings related to HIV prevention and care. Stigma contributes to a lack of attention to drug use screening, inadequate outreach to people who use drugs (PWUD) and insufficient uptake of services to prevent, treat, or mitigate HIV infection (and related consequences of drug use) among PWUD. Stigmas of interest include: internalized stigma among drug users, stigma associated with providing services to PWUD, and stigma toward PWUD by providers or service settings. Policies and practices that create or augment stigma also are of interest here, as well as stigma experienced by providers who might otherwise broaden their services to PWUD. Stigma reduction interventions for HIV service settings have been developed and, in some cases, implemented on a wide scale, but generally target sexual transmission as the primary behavioral risk; however, knowledge from this work can inform stigma among PWUD. Large literatures on stigma also exist in a variety of other conditions (e.g., cancer, mental illness) which also can provide conceptual and programmatic bases to speed the development of new interventions addressing PWUD.			
110034	Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings	National Institutes of Health/DHHS	NOT-MH-22-170	11-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 18-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 11-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103419	Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health	National Institutes of Health/DHHS	NOT-OD-21-100	10-Aug-2022	Not Specified
	<p>Contact Name Wendy Nelson, PhD, MPH</p> <p>Contact Telephone 240-276-6971</p> <p>Contact Email nelsonw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.</p>				
109009	Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities	National Institutes of Health/DHHS	NOT-EY-22-004	08-Aug-2022	Not Specified
	<p>Contact Name Jimmy Le, Sc.D.</p> <p>Contact Telephone 301-435-8160</p> <p>Contact Email Jimmy.Le@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022 , 05-Sep-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 17-Nov-2022 , 08-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 05-Apr-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 05-Sep-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 25-Jan-2025</p> <p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting research that aims to promote health equity in the prevention, treatment, and management of eye and vision conditions. Applications that target reduction of health disparities experienced by people who are visually impaired or blind are encouraged, as well as applications that investigate the impact of bias, structural racism, and discrimination in causing or sustaining eye or vision health inequities.</p>			
110865	Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy	National Institutes of Health/DHHS	NOT-CA-22-063	25-Jun-2022	Not Specified
	Contact Name	Yin Liu, Ph.D.			
	Contact Telephone	240-276-6251			
	Contact Email	liuy@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	<p>25-Jun-2022 , 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 26-Aug-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024</p>			
	Synopsis	<p>The overall goal of this Notice of Special Interest (NOSI) is to promote mechanistic research aimed at better understanding the pathophysiology of immune-related adverse events (irAEs). It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. The proposed research can be basic or translational but should be focused on revealing the mechanisms underlying irAEs. Single investigators and/or multidisciplinary teams with relevant expertise in the research area proposed and/or patient characterization and selection are encouraged to apply.</p>			
110328	RFA-RM-22-019 -- NIH Director's New Innovator Award Program (DP2 Clinical Trial Optional)	Office of the Director, National Institutes of Health/NIH/DHHS	RFA-RM-22-019	19-Aug-2022	1,500,000 USD
	Contact Name	Patricia (Trish) Labosky, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-594-4863
Contact Email	NewInnovatorAwards@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	19-Aug-2022
Synopsis	<p>The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director’s New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.</p>

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110884	FCO-- AMENDMENT -- NSF Regional Innovation Engines Broad Agency Announcement	National Science Foundation	NSFBAA-ENGINES-2022-05-1	30-Jun-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name Keith Boyea</p> <p>Contact Telephone</p> <p>Contact Email kboyea@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022 [LOI/Pre-App], 31-Aug-2022 [LOI/Pre-App], 29-Sep-2022</p> <p>Synopsis NSF Engines BAA Description This Broad Agency Announcement (BAA) is the first funding opportunity for the NSF Regional Innovation Engines (NSF Engines) program, a bold new initiative of the National Science Foundation that will create regional-scale innovation ecosystems throughout the United States. Providing up to \$160 million of funding for up to 10 years to establish each Engine, with up to an additional two years of development funding even before the official launch of an Engine, the program offers a unique opportunity to usher in a transformational revolution of economic growth by harnessing the Nation’s rich science and technology research enterprise and regional-level resources to address societal challenges and promote national competitiveness. This BAA provides an overview of the NSF Engines program and two current funding opportunities, Type-1 and Type-2 awards, open to coalitions led by U.S.-based for-profit businesses, non-profit organizations, and U.S. accredited institutions of higher education with a campus located in the U.S. Additionally, federally funded research and development centers, national laboratories, and state, local, and tribal governments (limited to agencies, offices, or divisions specifically dedicated to innovation, economic and/or workforce development) can receive NSF funds through subawards. KEY DEADLINES (by 5 p.m., submitter’s local time on the dates specified below). Failure to meet the established deadline date will result in the proposal not being reviewed. Type-1 and Type-2 Concept Outlines: Due June 30, 2022 Type-1 Letters of Intent: Due August 31, 2022 Type-1 Full Proposals: Due September 29, 2022 NSF anticipates accepting full proposals for Type-2 awards in FY23, on a date to be announced soon. Additional information on the NSF Engines program can be found here. Information for organizations who have not previously applied for federal grants: If your organization has not previously applied for a federal grant, your organization must obtain a Unique Entity Identifier (UEI), which is a 12-character alpha numeric value, and must also register in the System for Award management (SAM). Go to SAM.gov and complete the process through the “Register Your Entity or Get a Unique Entity ID” box. Scroll down on the site for FAQs. Note that registering with SAM.gov can take time so start the process very early in the application window!</p>				
110693	Resilient & Intelligent NextG Systems (RINGS) - Virtual Organization	National Science	22-590	01-Aug-2022	1,000,000

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Foundation			USD
	<p>Contact Name Alexander Sprintson</p> <p>Contact Telephone 703-292-8950</p> <p>Contact Email asprints@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The National Science Foundation (NSF) Directorate for Computer and Information Science and Engineering (CISE) and the Directorate for Engineering (ENG) solicit the submission of proposals to set up a Virtual Organization (VO) for the Resilient & Intelligent NextG Systems (RINGS) program. The RINGS program (NSF 21-581) is a partnership with the Office of the Under Secretary of Defense for Research and Engineering (OUSD R&E), the National Institute of Standards and Technology (NIST) and a number of industry partners to enhance both resiliency as well as performance across the various aspects of Next Generation (NextG) communications, networking and computing systems. The goal of this solicitation is to invite the submission of proposals to set up a Virtual Organization (VO) for the RINGS program. The VO will facilitate coordination, collaboration, and community-building across academia, government, and industrial partners. The VO will serve the broader RINGS community, including Principal Investigators (PIs), researchers, and students, to coordinate their efforts and streamline their interactions with the RINGS partners in order to reduce burden on and improve synergies within the PI community. The VO will work closely with the RINGS partners to build a strong and effective research community to bolster U.S. leadership across wireless, cloud, and networking sectors.</p>				
090168	ADVANCE: Organizational Change for Gender Equity in STEM Academic Professions (ADVANCE)	National Science Foundation	20-554	01-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name Jessie DeAro</p> <p>Contact Telephone 703-292-5350</p> <p>Contact Email ADVANCE@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 [LOI/Pre-App], 05-Aug-2022 , 06-Oct-2022 , 02-Nov-2022</p> <p>Synopsis The NSF ADVANCE program contributes to the National Science Foundation's goal of a more diverse and capable science and</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>engineering workforce. In this solicitation, the NSF ADVANCE program seeks to build on prior NSF ADVANCE work and other research and literature concerning gender, racial, and ethnic equity. The NSF ADVANCE program goal is to broaden the implementation of evidence-based systemic change strategies that promote equity for STEM faculty in academic workplaces and the academic profession. The NSF ADVANCE program provides grants to enhance the systemic factors that support equity and inclusion and to mitigate the systemic factors that create inequities in the academic profession and workplaces. Systemic (or organizational) inequities may exist in areas such as policy and practice as well as in organizational culture and climate. For example, practices in academic departments that result in the inequitable allocation of service or teaching assignments may impede research productivity, delay advancement, and create a culture of differential treatment and rewards. Similarly, policies and procedures that do not mitigate implicit bias in hiring, tenure, and promotion decisions could lead to women and racial and ethnic minorities being evaluated less favorably, perpetuating historical under-participation in STEM academic careers and contributing to an academic climate that is not inclusive.</p>				
111694	Dear Colleague Letter: Announcing Collaboration Opportunities in Responsible and Equitable AI under the U.S. National Science Foundation (NSF) and the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO)	National Science Foundation	NSF 22-086	01-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 703-292-5111</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 [LOI/Pre-App], 21-Sep-2022</p> <p>Synopsis NSF and CSIRO welcome proposals from joint teams of U.S. and Australian researchers on responsible and equitable artificial intelligence (AI). Proposals must present a unified research program collaboratively pursued by the U.S. and Australian team members. The research agenda must focus on new approaches to equitable and responsible AI and be aligned with one or more of the strategic priorities listed in the CSIRO Missions program.</p>				
108137	Dear Colleague Letter: NSF and William T. Grant Foundation Partnership to Increase the Use, Usefulness, and Impact of Research about Youth	National Science Foundation	NSF 22-035	03-Aug-2022	Not Specified
	<p>Contact Name Mary Feeney</p> <p>Contact Telephone</p> <p>Contact Email mfeeney@nsf.gov</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Aug-2022</p> <p>Synopsis With this Dear Colleague Letter (DCL), the Directorate for Social, Behavioral, and Economic Sciences (SBE) of the National Science Foundation (NSF) notifies the research community of a collaboration with the William T. Grant Foundation (WT Grant) on a coordinated call for proposals focused on increasing the public value of scientific research: "Increasing the Use, Usefulness and Impact of Research about Youth."</p>				
110943	Disaster Resilience Research Grants	National Science Foundation	22-593	19-Aug-2022	400,000 USD
	<p>Contact Name Jacqueline R. Meszaros</p> <p>Contact Telephone 703-292-7261</p> <p>Contact Email jmeszaro@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Aug-2022</p> <p>Synopsis With this joint solicitation, the NSF and the U.S Department of Commerce (DOC) National Institute for Standards and Technology (NIST) call for proposals for research to advance fundamental understanding of disaster resilience in support of improved, science-based planning, policy, decisions, design, codes, and standards.</p>				
107088	Science and Technology Centers: Integrative Partnerships	National Science Foundation	22-521	29-Aug-2022	150,000,000 USD
	<p>Contact Name Dragana Brzakovic</p> <p>Contact Telephone 703-292-5033</p> <p>Contact Email dbrzakov@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Aug-2022</p> <p>Synopsis The Science and Technology Centers (STC): Integrative Partnerships program supports exceptionally innovative, complex</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research and education projects that require large-scale, long-term awards. STCs focus on creating new scientific paradigms, establishing entirely new scientific disciplines and developing transformative technologies which have the potential for broad scientific or societal impact. STCs conduct world-class research through partnerships among institutions of higher education, national laboratories, industrial organizations, other public or private entities, and via international collaborations, as appropriate. They provide a means to undertake potentially groundbreaking investigations at the interfaces of disciplines and/or highly innovative approaches within disciplines. STCs may involve any area of science and engineering that NSF supports. STC investments support the NSF vision of creating and exploiting new concepts in science and engineering and providing global leadership in research and education. Centers provide a rich environment for encouraging future scientists, engineers, and educators to take risks in pursuing discoveries and new knowledge. STCs foster excellence in education by integrating education and research, and by creating bonds between learning and inquiry so that discovery and creativity fully support the learning process.

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109882	Peer Reviewed Medical Research Program--Focused Program Award	Department of the Army	W81XWH-22-PRMRP-FPA	12-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Aug-2022			
	Synopsis	The FY22 PRMRP Focused Program Award (FPA) is intended to optimize research and accelerate solutions to a critical question related to one of the congressionally directed FY22 PRMRP Topic Areas and one of the FY22 PRMRP Strategic Goals through a synergistic, multidisciplinary research program.			
110431	Tick-Borne Disease Research Program--Therapeutic/Diagnostic Research Award	Department of the Army	W81XWH-22-TBDRP-TDRA	25-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Aug-2022			
	Synopsis	The TBDRP's vision is to prevent the occurrence, better diagnose, and resolve or minimize the impact of Lyme disease and other tick-borne illnesses and conditions, with emphasis on burden of disease. The TBDRP's mission is to understand the pathogenesis of Lyme disease and other tick-borne illnesses and conditions; to deliver innovative solutions to prevent, diagnose, and treat their manifestations for the benefit of military Service Members and the American public; and to disseminate this knowledge. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The FY22 TBDRP Therapeutic/Diagnostic Research Award is intended to support hypothesis-driven therapeutic and diagnostic development research. Projects submitted under a Treatment Focus Area should be therapeutic evaluation studies designed to promote new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Projects submitted under a Diagnosis Focus Area should propose diagnostic approaches that will be readily integrated into clinical settings. All research projects should have a translational potential and			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					aim to improve patient care and/or the quality of life for military Service Members, Veterans, and their beneficiaries, as well as the American public living with Lyme disease and/or other tick-borne diseases.
111247	Lupus Research Program--Impact Award	Department of the Army	W81XWH-22-LRP-IPA	16-Aug-2022 [LOI/Pre-App]	750,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Aug-2022 [LOI/Pre-App], 01-Sep-2022			
	Synopsis	<p>The LRP's mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life for patients, including Service Members, Veterans, and beneficiaries. The LRP's vision is to cure lupus through partnership of scientists, clinicians, and consumers. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The LRP Impact Award encourages applications that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research and/or lupus disease. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through inferential reasoning and/or critical review and analysis of the literature. Inclusion of preliminary data is encouraged. The following are important aspects of the Impact Award:</p> <ul style="list-style-type: none"> • Impact: The proposed research, if successful, should impact an area of paramount importance in lupus disease. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. The Impact Award supports high-risk, high-reward studies that have the potential to make a significant advancement in lupus research. Research that represents an incremental advancement on previously published work is not considered impactful. • Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review. • Research Team: The research team's background should be appropriate with respect to its ability to successfully complete the proposed work. • Focus Areas: The proposed research must address at least one of the FY22 LRP Focus Areas. 			
111246	Lupus Research Program--Idea Award	Department of the Army	W81XWH-22-LRP-IA	16-Aug-2022 [LOI/Pre-App]	300,000 USD
	Contact Name				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Aug-2022 [LOI/Pre-App], 01-Sep-2022</p> <p>Synopsis The LRP’s mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life for patients, including Service Members, Veterans, and beneficiaries. The LRP’s vision is to cure lupus through partnership of scientists, clinicians, and consumers. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The LRP Idea Award supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. This award mechanism supports studies that have the potential to reveal entirely new avenues for investigation. The application must describe how the new idea will enhance the existing knowledge of lupus or develop a hypothesis(es) or an innovative and novel course of investigation. The Idea Award is not intended to support an incremental progression of an already established research project. Research completed through an Idea Award may generate sufficient preliminary data to enable the Principal Investigator (PI) to prepare an application for future research. Inclusion of preliminary data is not required. The following are important aspects of the Idea Award: <ul style="list-style-type: none"> • Innovation: Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. It is the responsibility of the PI to clearly and explicitly describe how the proposed research is innovative and will lead to novel avenues of investigation in lupus research. • Impact: The proposed research, if successful, should impact an area of paramount importance in lupus disease. Applications should clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. Research that represents an incremental advancement on previously published work is not considered impactful. • Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review. • Focus Areas: The proposed research must address at least one of the FY22 LRP Focus Areas. • Clinical trials are not allowed under this program announcement. </p>				
111620	Parkinson’s Research Program--Synergistic Idea Award	Department of the Army	W81XWH-22-PRP-SIA	16-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Aug-2022 [LOI/Pre-App], 01-Sep-2022</p> <p>Synopsis The PRP SIA supports new ideas that represent synergistic approaches to PD research involving two to four Principal Investigators (PIs) at the Assistant Professor (or equivalent) level or above. These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in Parkinson's research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. The PRP Synergistic Idea Award seeks applications from investigators working in a wide spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research.</p>				
111622	Parkinson's Research Program--Early Investigator Research Award	Department of the Army	W81XWH-22-PRP-EIRA	16-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Aug-2022 [LOI/Pre-App], 01-Sep-2022</p> <p>Synopsis The PRP EIRA supports research opportunities for investigators in the early stages of their careers, under the guidance of one or two designated Mentor(s). The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in PD research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship.</p>				
111243	Lupus Research Program--Transformative Vision Award	Department of the Army	W81XWH-22-LRP-TVA	16-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Aug-2022 [LOI/Pre-App], 01-Sep-2022			
	Synopsis	<p>The LRP’s mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life for patients, including Service Members, Veterans, and beneficiaries. The LRP’s vision is to cure lupus through partnership of scientists, clinicians, and consumers. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The TVA supports applications that will fulfill an extraordinary vision for dramatically improving the quality of life of persons with lupus using an intervention at the individual and/or healthcare system level. This award requires a plan that will test and achieve the vision through the translation of research ideas which, when addressed, will result in a near-term impact on the quality of life of persons living with lupus. Applications may address various quality-of-life issues in lupus patients of any age, including but not limited to those with disproportionate health burdens. Preliminary data are required. Human subject research and clinical trials are allowed under this program announcement. The following are important aspects of the Transformative Vision Award:</p> <ul style="list-style-type: none"> • Impact: The proposed research, if successful, should have a major impact on the quality of life of lupus patients. Applications should clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. The TVA supports high-risk, high-reward studies that have an intervention with the potential to make a significant, near-term impact on the quality of life of lupus patients. • Research Strategy: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review. • Focus Areas: The proposed research must address at least one of the FY22 LRP Focus Areas for the TVA. • Research Team: The research team’s background should be appropriate with respect to its ability to successfully complete the proposed work. • Consumer Advocate: Applications are required to include consumer advocate involvement. The research team must include one or more consumer advocate(s), who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with lupus or a caregiver, and they should be active in a lupus advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, lupus. The consumer advocate(s) should have a high level of knowledge of current lupus issues and the appropriate background or training in lupus research to contribute to the project. • Budget: The proposed budget should be appropriate for the 			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	proposed research and within the limitations of this program announcement.				
111621	Parkinson's Research Program--Investigator-Initiated Research Award	Department of the Army	W81XWH-22-PRP-IIRA	16-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Aug-2022 [LOI/Pre-App], 01-Sep-2022</p> <p>Synopsis</p>	<p>The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's research. This award mechanism supports the full spectrum of research from basic science through clinical research. The following are important aspects of the IIRA: • Research Strategy and Feasibility: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of the neurodegenerative effects of PD. Experimental strategies may be novel or may be based on strong rationale derived from previously published data, presented preliminary data, or literature review. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Preliminary data to support feasibility are encouraged but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or member(s) of the research team. The preliminary data must support the feasibility of the study. Clinical trials may be supported by this award mechanism and require the submission of Attachment 8: Regulatory Strategy. • Impact: The proposed research should impact an area of paramount importance in PD. The application must clearly and explicitly describe the potential short-term and long-term impact of the proposed study and convey its level of significance. The research should benefit individuals with PD. • Focus Areas: The proposed research must address at least one of the two FY22 PRP Focus Areas. • Principal Investigator and Research Team: The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. The application should demonstrate that the research team's background is appropriate to successfully achieving the proposed research and contributing to the field of PD research. • The PRP IIRA requires that the PI dedicate at least 15% of their full-time professional effort to this award during the award period.</p>			
111800	Breast Cancer Research Program--Breakthrough Award Level 4	Department of the Army	W81XWH-22-BCRP-BTA4-2	03-Aug-2022 [LOI/Pre-App]	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Aug-2022 [LOI/Pre-App], 02-Nov-2022</p>				
	Synopsis	<p>The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077897	Academy Leadership and Innovation Award	Academy of Criminal Justice Sciences		01-Aug-2022	600 USD
	Contact Name	Michele Bratina			
	Contact Telephone	301-446-6300			
	Contact Email	mbratina@wcupa.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	The Academy Leadership and Innovation Award will be given in recognition of a practitioner whose work has had a direct, positive, and significant effect on the criminal justice system, with a commitment to improving the criminal justice system. These contributions may include program development, policy implementation, education, training, direct services, research, and legislative action.			
	Applicant Types				
	Funding Limit	600.00 maximum			
	Limited Submission	No			
057243	Dissertation Scholarship	AHIMA Foundation		31-Aug-2022	9,000 USD
	Contact Name				
	Contact Telephone	312-233-1131			
	Contact Email	info@ahimafoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Aug-2022			
	Synopsis	The AHIMA Foundation annually offers scholarships to doctoral students who are in the stages of conducting research and writing their dissertation.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	9,000.00 maximum			
	Limited Submission	No			
057239	Merit Scholarships	AHIMA Foundation		31-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	312-233-1131			
	Contact Email	info@ahimafoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Aug-2022			
	Synopsis	AHIMA provides scholarships to students who have achieved academic excellence and demonstrate the potential to be future leaders in Health Information Management and Health Informatics.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
110963	Veteran's Scholarships	AHIMA Foundation		31-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	312-233-1131			
	Contact Email	info@ahimafoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	AHIMA provides scholarships to veteran military service members from the U.S. armed forces and spouses of veteran service members, including active-duty military, retirees, veterans, wounded warriors and surviving spouses. Applicants must be AHIMA members who are currently enrolled into a health information program accredited by CAHHIIM in the United States.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
020306	Grants Program	Alpha Foundation		01-Aug-2022	Not Specified
	Contact Name	John R. Wynn			
	Contact Telephone	256-713-2277			
	Contact Email	info@alphafoundationhsv.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	Since its formation in 1997, the Alpha Foundation has been dedicated to improving the human condition. To this end, Alpha will select organizations to which grants will be made that further this objective. An emphasis will be placed on grants to educational, scientific, and charitable organizations. A major focus of Alpha's support is biotechnology to aid in the discovery and cure of diseases.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
111574	Trial Capacity Awards	ALS Association		29-Jun-2022 [LOI/Pre-App]	400,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email researchgrants@alsa-national.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jun-2022 [LOI/Pre-App], 31-Aug-2022</p> <p>Synopsis The ALS Association's Trial Capacity program provides up to \$400,000 in total funding over four years to support efforts to increase participation in ALS clinical trials and efforts to improve the speed and efficiency of clinical trial conduct at both established and emerging ALS clinical trial sites.</p> <p>Applicant Types</p> <p>Funding Limit 400,000.00 maximum</p> <p>Limited Submission No</p>				
083359	Bi-Annual Grant	Alzheimer's Foundation of America		26-Aug-2022	6,000 USD
	<p>Contact Name</p> <p>Contact Telephone 866-232-8484</p> <p>Contact Email membership@alzfdn.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Aug-2022</p> <p>Synopsis The Bi-Annual Grant seeks proposals from AFA's nonprofit member organizations in good standing (membership dues must be paid up-to-date) for new or existing programs and services that improve the lives of those affected by Alzheimer's disease or a related dementia. The amount to be requested is \$6,000. This grant is offered bi-annually in the spring and the fall of each year.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 6,000.00 maximum Limited Submission No				
076118	Clinician Scientist Development Award in Multiple Sclerosis	American Academy of Neurology		10-Aug-2022 [LOI/Pre-App]	Not Specified
	Contact Name Walt Kostich, PhD Contact Telephone Contact Email walter.kostich@nmss.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 10-Aug-2022 [LOI/Pre-App], 17-Aug-2022 Synopsis This National MS Society-ABF MS Clinician Scientist Development Award will support the training of young clinicians committed to careers in academic medicine with an emphasis on MS clinical research. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
064844	Innovations Program	American Association for Anatomy		16-Aug-2022	50,000 USD
	Contact Name Contact Telephone 301-563-9454 Contact Email info@anatomy.org Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 16-Aug-2022 Synopsis The Innovations Program provides funding to support new scientific, educational, and professional development programs and services developed by members and/or Committees. Grant recipients receive up to \$50,000. Applicant Types Funding Limit 50,000.00 maximum Limited Submission No				
071751	Competitive Research Grants	American Association of Endodontists Foundation		15-Aug-2022	Not Specified
	Contact Name Contact Telephone 312-266-7255 Contact Email foundation@aae.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Aug-2022 Synopsis The Foundation for Endodontics awards grants to inspire and support clinical research and the genesis of new knowledge in endodontics. The research grant initiative ensures the growth and development of the science of endodontics and improves the quality of patient care. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
040654	External Grants Program	American Chestnut Foundation (TACF)		01-Aug-2022	10,000 USD
	Contact Name Contact Telephone 828-281-0047				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email externalgrants@acf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The American Chestnut Foundation (TACF) is pleased to announce its annual request for research proposals. They will entertain any research proposal concerned with any aspect of chestnut biology that addresses their core mission - to return the iconic American chestnut to its native range.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
017212	Annual Outstanding Contributions to Epidemiology Award	American College of Epidemiology		05-Aug-2022	Not Specified
	<p>Contact Name Xinzhi Zhang, MD, PhD, Awards Committee Chair</p> <p>Contact Telephone 518-240-1210</p> <p>Contact Email Xinzhi.Zhang@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Aug-2022</p> <p>Synopsis This award recognizes an active epidemiologist for outstanding contributions to the field in one of three areas: methods development; etiologic research; or applied epidemiology. The award is conferred each year at the Annual Meeting, and the recipient is invited to deliver a platform talk during the Annual Meeting. The awardee will receive a monetary prize and complementary annual meeting registration.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
071713	Medical and Graduate Student Research Preceptorship	American College of Rheumatology		01-Aug-2022	4,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022 , 01-Nov-2022 , 01-Feb-2023			
	Synopsis	The Medical and Graduate Student Preceptorship program introduces medical and graduate students to rheumatology-related health care by supporting a 4-Week or 8-Week, full-time clinical or research experience in the broad area of rheumatic disease.			
	Applicant Types				
	Funding Limit	4,000.00 see detail			
	Limited Submission	No			
093259	Medical and Graduate Student Achievement Award	American College of Rheumatology		01-Aug-2022	1,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Student Achievement Awards recognize outstanding medical and graduate students for significant work in the field of rheumatology and to provide students with the opportunity to attend the ACR Annual Meeting.			
	Applicant Types				
	Funding Limit	1,000.00 see detail			
	Limited Submission	No			
010661	Ephraim P. Engleman Endowed Resident Research Preceptorship	American College of Rheumatology		01-Aug-2022	15,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	foundation@rheumatology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022 , 01-Nov-2022 , 01-Feb-2023			
	Synopsis	The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The applicant must present a budget not to exceed \$15,000.			
	Applicant Types				
	Funding Limit	15,000.00 maximum			
	Limited Submission	No			
048482	Pathway to Stop Diabetes - Accelerator Award (ACE)	American Diabetes Association, Inc.		01-Aug-2022	1,625,000 USD
	Contact Name				
	Contact Telephone	800-342-2383			
	Contact Email	pathway@diabetes.org			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The Pathway to Stop Diabetes Program intends to attract brilliant scientists at the peak of their creativity to diabetes research, and to accelerate their research progress by providing the necessary resources and support for conducting transformative science. The Accelerator Award is designed to support exceptional, independent early-career researchers who have distinguished themselves as promising investigators and are in the beginning stages of establishing successful, sustainable diabetes research programs.</p> <p>Applicant Types</p> <p>Funding Limit 325,000.00 per year</p> <p>Limited Submission Yes</p>				
048481	Pathway to Stop Diabetes - Initiator Award (INI)	American Diabetes Association, Inc.		01-Aug-2022	1,625,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-342-2383</p> <p>Contact Email pathway@diabetes.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The Pathway to Stop Diabetes Program intends to attract brilliant scientists at the peak of their creativity to diabetes research, and to accelerate their research progress by providing the necessary resources and support for conducting transformative science. The Initiator Award is a two-phased award designed to support the transition of scientists from mentored training to independent research faculty.</p> <p>Applicant Types</p> <p>Funding Limit 1,625,000.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes			
083816	AGA-Pilot Research	American Gastroenterological Association		23-Aug-2022	30,000 USD
	Contact Name				
	Contact Telephone	301-654-2055			
	Contact Email	awards@gastro.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Aug-2022			
	Synopsis	This award provides \$30,000 for one year to recipients at any career stage establishing new research projects in health and health care disparities in digestive diseases.			
	Applicant Types				
	Funding Limit	30,000.00 maximum			
	Limited Submission	No			
110783	AGA-Pfizer Pilot Research Award in Non-Alcoholic Steatohepatitis	American Gastroenterological Association		23-Aug-2022	30,000 USD
	Contact Name				
	Contact Telephone	301-654-2055			
	Contact Email	awards@gastro.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This award provides \$30,000 for one year to independent investigators at any career stage researching new directions to improve the diagnosis and treatment of non-alcoholic steatohepatitis (NASH).</p> <p>Applicant Types </p> <p>Funding Limit 30,000.00 maximum</p> <p>Limited Submission No</p>				
008669	Merit Scholarships	American Health Information Management Association		31-Aug-2022	2,500 USD
	<p>Contact Name </p> <p>Contact Telephone 312-233-1445</p> <p>Contact Email info@ahimafoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis One of the major initiatives of the AHIMA Foundation is to attract and support new talent in the health information management (HIM) industry by improving educational opportunities for current and future HIM professionals through scholarships. The AHIMA Foundation annually offers merit scholarships to currently enrolled outstanding undergraduates in HIM and health information technology (HIT) as well as those professionals pursuing master's or doctoral degrees in areas related to health information.</p> <p>Applicant Types </p> <p>Funding Limit 2,500.00 maximum</p> <p>Limited Submission No</p>				
067802	Discovery Grants	American Hearing Research Foundation		15-Aug-2022	50,000 USD
	<p>Contact Name </p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 630-617-5079</p> <p>Contact Email info@american-hearing.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Aug-2022</p> <p>Synopsis The American Hearing Research Foundation (AHRF) typically funds six to 10 regular research grants that investigate various aspects of hearing and balance disorders related to the inner ear. Grants are for \$20,000 to \$50,000 for one year of research.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				
004164	William M. Feinberg Award for Excellence in Clinical Stroke	American Heart Association		08-Aug-2022	2,000 USD
	<p>Contact Name Ashley Savage</p> <p>Contact Telephone 214-706-1009</p> <p>Contact Email Ashley.Savage@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Aug-2022</p> <p>Synopsis The Feinberg recipient presents a lecture on stroke each year at the International Stroke Conference (ISC). The award recognizes ongoing contributions to the investigation and management of stroke – clinical science.</p> <p>Applicant Types</p> <p>Funding Limit 2,000.00 see detail</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
079373	BCVS Abstract Travel Award	American Heart Association		24-Aug-2022	350 USD
	Contact Name				
	Contact Telephone	214-706-1181			
	Contact Email	Council.Awards@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-Aug-2022			
	Synopsis	The Basic Cardiovascular Abstract Travel Grant recognizes meritorious work by early career investigators and provides a travel grant to attend the AHA's Scientific Sessions to those whose abstracts place in the top 20 percent of their category.			
	Applicant Types				
	Funding Limit	350.00 see detail			
	Limited Submission	No			
004159	Robert G. Siekert New Investigator Award	American Heart Association		23-Aug-2022	1,500 USD
	Contact Name				
	Contact Telephone	214-706-1009			
	Contact Email	StrokProgPart@heart.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis Applicant Types Funding Limit Limited Submission	The American Heart Association provides an award, in honor of Robert G. Siekert, to encourage new investigators to undertake or continue stroke-related research. 1,500.00 see detail No			
004160	Mordecai Y.T. Globus New Investigator Award in Stroke	American Heart Association		23-Aug-2022	1,500 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	Ashley Savage 214-706-1009 ashley.savage@heart.org Link to sponsor website Link to program URL 23-Aug-2022 , 29-Aug-2022 This award recognizes Dr. Mordecai Y.T. Globus' major contributions to research in cerebrovascular disease and his outstanding contributions to the elucidation of the role of neurotransmitters in ischemia and trauma; the interactions among multiple neurotransmitters; the mechanisms of hypothermic neuroprotection; and the role of oxygen radical mechanisms and nitric oxide in brain injury. 1,500.00 see detail No			
004162	Stroke Care in Emergency Medicine Award	American Heart Association		23-Aug-2022	1,500 USD
	Contact Name Contact Telephone	 214-706-1009			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email StrokProgPart@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022</p> <p>Synopsis The Stroke Care in Emergency Medicine Award encourages investigators to undertake or continue research in the emergent phase of acute stroke treatment and submit an abstract to the International Stroke Conference.</p> <p>Applicant Types</p> <p>Funding Limit 1,500.00 see detail</p> <p>Limited Submission No</p>				

079372	ATVB Scientific Sessions Travel Awards for Early Career Investigators	American Heart Association		24-Aug-2022	500 USD
--------	---	----------------------------	--	-------------	---------

	<p>Contact Name</p> <p>Contact Telephone 214-706-1181</p> <p>Contact Email Council.Awards@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Aug-2022</p> <p>Synopsis The Council on Arteriosclerosis, Thrombosis, and Vascular Biology Scientific Sessions Travel Grants for Early Career Investigators encourage and support the efforts of early career investigators in cardiovascular research, and encourages early career investigators, women and under-represented minorities to participate in ATVB and other AHA activities.</p> <p>Applicant Types</p> <p>Funding Limit 500.00 maximum</p>				
--	--	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
088236	Canine Health Research (RFP)	American Kennel Club Canine Health Foundation		18-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	888-682-9696			
	Contact Email	chfgrants@akcchf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Aug-2022			
	Synopsis	The mission of the AKC Canine Health Foundation (CHF) is to advance the health of all dogs and their owners by funding sound scientific research and supporting the dissemination of health information to prevent, treat and cure canine disease. CHF supports a One Health model as a critical tool to achieving this vision, with a multidisciplinary approach to addressing the health needs of all dogs and their people.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
033877	Research Grant	American Nephrology Nurses' Association		31-Aug-2022 [Optional]	15,000 USD
	Contact Name				
	Contact Telephone	888-600-2662			
	Contact Email	jennifer.carroll@annanurse.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 31-Aug-2022 [Optional], 15-Nov-2022 Synopsis Each year, ANNA offers grants to fund research projects. Recipients are announced annually at the ANNA National Symposium. Applicant Types Funding Limit 15,000.00 maximum Limited Submission No				
033878	Evidence-Based Practice Project Grants	American Nephrology Nurses' Association		31-Aug-2022 [Optional]	5,000 USD
	Contact Name Contact Telephone 856-256-2320 Contact Email jennifer.carroll@annanurse.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Aug-2022 [Optional], 15-Nov-2022 Synopsis Evidence-Based Practice Project Grants are offered to fund qualified nephrology nurses' work to translate research into practice in support of developing evidence-based nephrology nursing practice and demonstrating the value of nephrology nursing in improving patient outcomes. Applicant Types Funding Limit 5,000.00 maximum Limited Submission No				
013296	Young Scientist Research Award	American Oil Chemists' Society		01-Aug-2022	2,500 USD
	Contact Name Contact Telephone 217-359-2344				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email awards@aoacs.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Aug-2022 Synopsis The AOCS Young Scientist Research Award recognizes a young scientist who has made a significant and substantial research contribution in one of the areas represented by AOCS Divisions. Applicant Types Funding Limit 2,500.00 see detail Limited Submission No				
020918	Ralph Holman Lifetime Achievement Award	American Oil Chemists' Society		01-Aug-2022	500 USD
	Contact Name Victoria Santo Contact Telephone 217-359-2344 Contact Email victoria@aoacs.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Aug-2022 Synopsis The Ralph Holman Lifetime Achievement Award, sponsored by the Health and Nutrition Division, recognizes significant lifetime and meritorious achievements in areas of interest to the Health and Nutrition Division. Applicant Types Funding Limit 500.00 see detail Limited Submission No				
013761	Schroepfer Medal	American Oil Chemists' Society		15-Aug-2022	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone 217-359-2344 Contact Email awards@aocs.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Aug-2022 Synopsis The Schroepfer Medal recognizes a scientist who has made significant and distinguished advances in the steroid field. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
053975	John Howland Award	American Pediatric Society		01-Aug-2022	5,000 USD
	Contact Name Contact Telephone 346-980-9710 Contact Email info@aps1888.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Aug-2022 Synopsis The John Howland Award is bestowed annually upon an esteemed pediatric leader whose significant contributions have advanced child health and the profession of pediatrics. Applicant Types Funding Limit 5,000.00 see detail Limited Submission No				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
033695	ASPEN Rhoads Research Foundation Annual Grants	American Society for Parenteral and Enteral Nutrition		01-Aug-2022	25,000 USD
	Contact Name				
	Contact Telephone	301-587-6315			
	Contact Email	foundation@nutritioncare.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	The ASPEN Rhoads Research Foundation funds exceptional scientific research projects submitted by early-career investigators of clinical nutrition and metabolic support in alignment with the priorities outlined in the ASPEN Research Agenda.			
	Applicant Types				
	Funding Limit	25,000.00 see detail			
	Limited Submission	No			
004643	General Surgery Resident Research Initiation Grant	American Society of Colon and Rectal Surgeons		15-Aug-2022	20,000 USD
	Contact Name				
	Contact Telephone	847-607-6410			
	Contact Email	rf@fascrs.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of the General Surgery Resident Research Initiation Grant is to attract General Surgery Residents into the field of colon and rectal surgery by providing opportunities to engage in clinical or laboratory-based research focused on diseases of the colon, rectum and anus. The grant provides \$20,000 for a period of one year.			
	Applicant Types				
	Funding Limit	20,000.00 per year			
	Limited Submission	No			
011588	ASH Scholar Award -- Scholar Award for Junior Faculty	American Society of Hematology		01-Aug-2022	150,000 USD
	Contact Name				
	Contact Telephone	202-776-0544			
	Contact Email	awards@hematology.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	<p>The ASH Scholar Awards are designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator. The Scholar Award for Junior Faculty provides up to \$150,000 over a two- to three-year period in equal quarterly payments over the award term. MD/DO, PhD or MD/DO-PhD applicants must have more than eight years (96 months) and 13 or fewer years (156 months) of research experience after completion of their terminal degree (including research performed during fellowship but excluding clinical fellowship time).</p> <p>Applicants with more than 5 years (60 months) and eight or fewer years (96 months) of research experience who have already received, or do not meet the eligibility requirements for the Fellow to Faculty Scholar Award, are eligible to apply for the Junior Faculty Scholar Award. Applicants who hold independent faculty level positions (Assistant Professor, or equivalent – which may be indicated by having achieved the appointment after an external search and/or if the individual has voting rights as a member of the faculty) must apply for the Junior Faculty Award,</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>regardless of research experience. Individuals serving as an ‘acting’ faculty member may be excluded from this requirement.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 maximum</p> <p>Limited Submission No</p>				
058656	Carl Koller Memorial Research Grant	American Society of Regional Anesthesia and Pain Medicine		15-Aug-2022 [LOI/Pre-App]	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone 412-471-2718</p> <p>Contact Email asraassistant@asra.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Aug-2022 [LOI/Pre-App], 12-Dec-2022</p> <p>Synopsis The Carl Koller Memorial Research Grant supports clinical and laboratory studies related to any aspect of regional anesthesia and analgesia and their application to surgery.</p> <p>Applicant Types</p> <p>Funding Limit 200,000.00 maximum</p> <p>Limited Submission No</p>				
111664	Trial Capacity Awards	Amyotrophic Lateral Sclerosis Association		29-Jun-2022 [LOI/Pre-App]	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email researchgrants@alsa-national.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 29-Jun-2022 [LOI/Pre-App], 31-Aug-2022 Synopsis The Clinical Trial Capacity Awards will support efforts to increase the number and diversity of people living with ALS who have the opportunity to participate in clinical trials, and efforts to improve the speed and efficiency of clinical trial conduct at both established and emerging clinical trial sites across the US. Applicant Types Funding Limit 400,000.00 maximum Limited Submission No				
066425	Technologist Travel Award	Association for Molecular Pathology		30-Aug-2022	1,500 USD
	Contact Name Contact Telephone 301-634-7987 Contact Email amp@amp.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 30-Aug-2022 Synopsis The AMP Technologist Travel Award provides up to \$1,500 in travel assistance to the Annual Meeting & Expo for up to three (3) selected AMP member technologists who do not receive travel support from their institutions. Applicant Types Funding Limit 1,500.00 maximum Limited Submission No				
071110	Research Grants	Benign Essential Blepharospasm Research Foundation (BEBRF)		31-Aug-2022	100,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 409-832-0788</p> <p>Contact Email bebrf@blepharospasm.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis BEBRF will provide funds to support research directly related to blepharospasm or Meige's Syndrome, both forms of cranial dystonia.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
089251	Medical Education Grants - United States	Biogen, Inc.		15-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 617-914-1299</p> <p>Contact Email grantsandgiving@biogen.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Aug-2022 , 01-Nov-2022</p> <p>Synopsis Biogen provides funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited. Biogen is currently accepting requests in Alzheimer's Disease, Biosimilars (Ophthalmology), Multiple Sclerosis, and Spinal Muscular Atrophy.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 not provided			
	Limited Submission	No			
089255	General Grants - United States	Biogen, Inc.		15-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	617-914-1299			
	Contact Email	grantsandgiving@biogen.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022 , 01-Nov-2022			
	Synopsis	Biogen provides funding to an eligible institution or organization to support a program or project that does not fit any of the other defined grant categories. Biogen considers requests in Biosimilars (Ophthalmology), Multiple Sclerosis, and Spinal Muscular Atrophy.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
109420	Patient Education Grants - United States	Biogen, Inc.		15-Aug-2022	Not Specified
	Contact Name				
	Contact Telephone	617-914-1299			
	Contact Email	grantsandgiving@biogen.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022 , 01-Nov-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis Applicant Types Funding Limit Limited Submission	Biogen provides funding to an eligible institution or organization to support independent educational activities for patients or caregivers. Biogen considers requests in Biosimilars (Ophthalmology), Multiple Sclerosis, and Spinal Muscular Atrophy. 0.00 not provided No			
015674	Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research	Brandeis University		31-Aug-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	781-736-2400 Link to sponsor website Link to program URL 31-Aug-2022 The Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research was established as an expression of the conviction that educational institutions have an important role to play in the encouragement and development of basic science as it applies to medicine. A cash prize and a medallion accompany each award. 0.00 see detail No			
045337	BSI Conference Travel Grants	British Society for Immunology		01-Aug-2022	1,220 USD
	Contact Name Contact Telephone	+44 (0)20 3019 5901			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email membership@immunology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 , 01-Nov-2022</p> <p>Synopsis The BSI provides support to members to facilitate their attendance at scientific conferences and seminars in the UK and around the world. Maximum awards are currently as follows: £500 for travel within the UK; £700 for European travel and £1,000 for the rest of the world.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 maximum</p> <p>Limited Submission No</p>				
045367	Partnering Opportunity for Late Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine		30-Jun-2022	6,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 510-340-9101</p> <p>Contact Email clinical@cirm.ca.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jun-2022 , 29-Jul-2022 , 31-Aug-2022 , 30-Sep-2022 , 31-Oct-2022 , 30-Nov-2022 , 30-Dec-2022</p> <p>Synopsis The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this program announcement is to support late-stage preclinical studies necessary to file and attain an active IND or IDE with the Food and Drug Administration (FDA) and initiate start-up activities to prepare for a clinical trial for a regenerative medicine therapy (stem cell-based or genetic therapy). Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p> <p>6,000,000.00 maximum</p> <p>No</p>			
045538	Partnering Opportunity For Clinical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine		30-Jun-2022	Not Specified

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p></p> <p>510-340-9101</p> <p>Clinical@cirm.ca.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>30-Jun-2022 , 29-Jul-2022 , 31-Aug-2022 , 30-Sep-2022 , 31-Oct-2022 , 30-Nov-2022 , 30-Dec-2022</p> <p>The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this funding opportunity is to support completion of a clinical trial for a regenerative medicine-based therapy (stem cell-based or genetic therapy) that addresses an unmet medical need. Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.</p> <p></p> <p>0.00 see detail</p> <p>No</p>
---	---

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110024	Clinical Trial Grant	Cannonball Kids' Cancer Foundation		15-Aug-2022 [LOI/Pre-App]	200,000 USD
	Contact Name	Matt Kopkin, Grants Administrator			
	Contact Telephone	321-325-5392			
	Contact Email	grants@cannonballkidscancer.org			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	15-Aug-2022 [LOI/Pre-App]			
	Synopsis	The purpose of Cannonball Kids' cancer (CKc) Foundation Clinical Research Grants is to provide critical funding for promising clinical research studies to investigate novel treatments for pediatric cancers.			
	Applicant Types				
	Funding Limit	200,000.00 maximum			
	Limited Submission	No			
110025	Program Grants	Cannonball Kids' Cancer Foundation		15-Aug-2022 [LOI/Pre-App]	65,000 USD
	Contact Name	Matt Kopkin, Grants Administrator			
	Contact Telephone	321-325-5392			
	Contact Email	grants@cannonballkidscancer.org			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	15-Aug-2022 [LOI/Pre-App]			
	Synopsis	The purpose of Cannonball Kids' cancer (CKc) Foundation Clinical Research Grants is to provide critical funding for promising clinical research studies to investigate novel treatments for pediatric cancers.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 65,000.00 maximum Limited Submission No				
110026	Young Investigator Grant	Cannonball Kids' Cancer Foundation		15-Aug-2022 [LOI/Pre-App]	100,000 USD
	Contact Name Matt Kopkin, Grants Administrator Contact Telephone 321-325-5392 Contact Email grants@cannonballkidscancer.org Sponsor Website Link to sponsor website Program URL Deadline Dates (ALL) 15-Aug-2022 [LOI/Pre-App] Synopsis The purpose of Cannonball Kids' cancer (CKc) Foundation Clinical Research Grants is to provide critical funding for promising clinical research studies to investigate novel treatments for pediatric cancers. Applicant Types Funding Limit 100,000.00 maximum Limited Submission No				
005450	Clinical Research Award	Cystic Fibrosis Foundation		08-Aug-2022	Not Specified
	Contact Name Contact Telephone 301-841-2637 Contact Email grants@cff.org Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-Aug-2022</p> <p>Synopsis Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation’s mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical (observational/interventional), translational or epidemiologic study approaches.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
110359	Program for Clinical Trials in Organ Transplantation (CTOT) Ancillary Studies	Cystic Fibrosis Foundation		23-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email lungtransplant@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Aug-2022</p> <p>Synopsis The Cystic Fibrosis Foundation (CFF) is requesting letters of intent for research projects that aim to use available clinical trials in organ transplantation specimens and/or clinical data to improve knowledge of chronic lung allograft dysfunction pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of chronic lung allograft dysfunction. Funding will vary based on the type of proposal. Hypothesis-generating or data only research may receive up to \$50,000 per year for up to two years, plus 12% indirect cost. Hypothesis-based research using both specimen and data may receive up to \$100,000 per year for up to two years, plus 12% indirect costs may be requested.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
061719	Seedcorn Funding Programme	Cystinosis Ireland		31-Aug-2022	10,500 USD
	Contact Name	Ruth Davis, Research Manager			
	Contact Telephone	01 687 5758			
	Contact Email	ruth.davis@cystinosis.ie			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Aug-2022 , 30-Nov-2022			
	Synopsis	The Cystinosis Seedcorn Funding Programme aims to provide researchers with the opportunity to generate solid preliminary data which would contribute to a sustainable, longer-term application for funding. Funding is available to research institutions worldwide.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
020270	Damon Runyon Fellowship Award	Damon Runyon Cancer Research Foundation		15-Aug-2022	52,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	awards@damonrunyon.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Aug-2022 , 15-Mar-2023</p> <p>Synopsis The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Candidates must apply for the fellowship under the guidance of a Sponsor—a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow. In addition to aiding in the planning, execution and supervision of the proposed research, the sponsor’s role is to foster the development of the Fellow’s overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The sponsor is also expected to assist the Fellow in attaining their career goals. Candidates applying to work in foreign-based or United States government laboratories may be awarded a fellowship if the program represents an unusual opportunity for postdoctoral training. Foreign candidates may apply to do their research only in the United States.</p> <p>Applicant Types</p> <p>Funding Limit 52,000.00 for the first year</p> <p>Limited Submission No</p>				
037090	Fellows Research Grant	Endocrine Fellows Foundation		10-Aug-2022	7,500 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email info@endocrinefellows.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Aug-2022</p> <p>Synopsis The Foundation has long recognized the difficulty in training new thought leaders in clinical and basic science. Funding and support for fellows remains quite limited both during their training and as they move into nascent academic careers. Our Fellows Research Grant Program is an integral part of what we do to support fellows and junior investigators. Obtaining new grants is often dependent on prior grant recipient history and the ability of fellows to successfully initiate new research projects. This is critical for further long-term career development. A</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>rigorous MD peer-reviewed grant process gives a very thorough high-level evaluation and feedback to all fellows who participate. Grant awardees whose projects pass this rigorous review can utilize these projects as springboard to future success in the field, creating our leaders of tomorrow.</p> <p>Applicant Types</p> <p>Funding Limit 7,500.00 maximum</p> <p>Limited Submission No</p>				
111141	EU4Health Programme (EU4H) -- Action Grant to Support a HERA Laboratory Network	European Commission	EU4H-2021-PJ-20	18-Aug-2022	26,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email HADEA-HP-CALLS@ec.europa.eu</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Aug-2022</p> <p>Synopsis This action supports the policy priority to respond to the COVID-19 crisis and to enhance preparedness for future health emergencies with the particular emphasis on intelligence gathering to support the timely provision of medical countermeasures. It implements the EU4Health Programme’s general objective of protecting people in the Union from serious cross-border threats to health and strengthening the responsiveness of health systems and coordination among the Member States to cope with serious cross-border threats to health (Article 3, point (b)) through the specific objectives defined in Article 4, points (b) and (c), of Regulation (EU) 2021/522. This action aims to establish a pilot network of top-class laboratories and research institutes that have the critical expertise and capacities to provide the information needed in the shortest possible timeframe and to support HERA in identifying emergent pathogens and ensuring the availability of medical countermeasures for improved health preparedness and response.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	25,000,000.00 maximum			
	Limited Submission	No			
009742	ECCO Travel Awards	European Crohn's and Colitis Organisation		01-Aug-2022	1,575 USD
	Contact Name				
	Contact Telephone	+43-01-710 2242-0			
	Contact Email	ecco@ecco-ibd.eu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	The European Crohn's and Colitis Organisation (ECCO) offers Travel Awards as an opportunity for young investigators to visit different Inflammatory Bowel Disease (IBD) centres in Europe, to learn scientific techniques or to become clinical observers.			
	Applicant Types				
	Funding Limit	1,500.00 maximum			
	Limited Submission	No			
048728	N-ECCO Travel Award	European Crohn's and Colitis Organisation		01-Aug-2022	1,575 USD
	Contact Name				
	Contact Telephone	+43-01-710 2242-0			
	Contact Email	ecco@ecco-ibd.eu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The European Crohn’s and Colitis Organisation (ECCO) offers the N-ECCO Travel Award as an opportunity for IBD nurses to visit a different Inflammatory Bowel Disease (IBD) centre in Europe and to observe and learn from IBD nursing services of another centre. This travel award aims to enhance the opportunity for IBD nurses to visit European centres. They are not designed to support travel to congresses or meetings.</p> <p>1,500.00 see detail</p> <p>No</p>			

009737	ECCO Grants	European Crohn's and Colitis Organisation		01-Aug-2022	84,000 USD
--------	-----------------------------	---	--	-------------	------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p></p> <p>+43-01-710 2242-0</p> <p>ecco@ecco-ibd.eu</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Aug-2022</p> <p>The European Crohn’s and Colitis Organisation (ECCO) offers Research Grants to promote innovative scientific research in the area of Inflammatory Bowel Diseases (IBD) in Europe. ECCO Grants are designed to support IBD Research within the country of affiliation. Typically, research for ECCO Grant projects is undertaken in the home institution of the applicant. The target audience are young basic/clinical scientists: not older than 40 years; or if older than 40 years, who are within 5 years of the date of completion of their GI training or PhD graduation (a certificate needs to be provided). Up to eight ECCO Grants may be given each year.</p> <p>80,000.00 maximum</p> <p>Yes</p>
---	---

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
000277	Mentored Research Training Grants (MRTG)	Foundation for Anesthesia Education & Research		15-Aug-2022	250,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			
	Contact Email	FAER@faer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			
	Synopsis	Mentored Research Training Grants (MRTG) help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators. Eligible applicants are faculty members who have completed their core anesthesiology residency within the past ten years. Grants of up to \$250,000 will be awarded for a duration of two years.			
	Applicant Types				
	Funding Limit	125,000.00 per year			
	Limited Submission	No			
000512	Research Fellowship Grant (RFG)	Foundation for Anesthesia Education & Research		15-Aug-2022	75,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			
	Contact Email	FAER@faer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Research Fellowship Grants (RFG) are intended to provide anesthesiology residents and fellows with the opportunity to obtain significant training in research techniques and scientific methods. The RFG is a one-year (12-month), \$75,000 primary investigator (no co-investigators) award for anesthesiology trainees after the CA-1 year. The RFG is awarded in conjunction with clinical training in an anesthesiology residency or fellowship program. The RFG requires 80 percent research time.			
	Applicant Types				
	Funding Limit	75,000.00 maximum			
	Limited Submission	No			
109469	Translational Pipeline Program	Fox (Michael J.) Foundation for Parkinson's Research		11-Aug-2022	2,000,000 USD
	Contact Name				
	Contact Telephone	800-708-7644			
	Contact Email	grants@michaeljfox.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Aug-2022			
	Synopsis	The Translational Pipeline Program seeks to foster and accelerate the development of Parkinson's disease therapeutics with potential for fundamentally altering disease course or significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. The award amount ranges from \$250,000 - \$2 million (greater funding may be considered).			
	Applicant Types				
	Funding Limit	2,000,000.00 maximum			
	Limited Submission	No			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																																		
109472	Biomarkers to Support Therapeutic Trials Program	Fox (Michael J.) Foundation for Parkinson's Research		11-Aug-2022	300,000 USD																																																		
	<table border="0" style="width: 100%;"> <tr> <td style="width: 25%;">Contact Name</td> <td colspan="4"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="4">1-800-708-7644</td> </tr> <tr> <td>Contact Email</td> <td colspan="4">grants@michaeljfox.org</td> </tr> <tr> <td>Sponsor Website</td> <td colspan="4">Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td colspan="4">Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="4">11-Aug-2022</td> </tr> <tr> <td>Synopsis</td> <td colspan="4">The Michael J. Fox Foundation offers the Biomarkers to Support Therapeutic Trials Program to fund outcome measures which will directly inform and transform therapeutic development. Funding is up to \$300,000.</td> </tr> <tr> <td>Applicant Types</td> <td colspan="4"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="4">300,000.00 maximum</td> </tr> <tr> <td>Limited Submission</td> <td colspan="4">No</td> </tr> </table>					Contact Name					Contact Telephone	1-800-708-7644				Contact Email	grants@michaeljfox.org				Sponsor Website	Link to sponsor website				Program URL	Link to program URL				Deadline Dates (ALL)	11-Aug-2022				Synopsis	The Michael J. Fox Foundation offers the Biomarkers to Support Therapeutic Trials Program to fund outcome measures which will directly inform and transform therapeutic development. Funding is up to \$300,000.				Applicant Types					Funding Limit	300,000.00 maximum				Limited Submission	No			
Contact Name																																																							
Contact Telephone	1-800-708-7644																																																						
Contact Email	grants@michaeljfox.org																																																						
Sponsor Website	Link to sponsor website																																																						
Program URL	Link to program URL																																																						
Deadline Dates (ALL)	11-Aug-2022																																																						
Synopsis	The Michael J. Fox Foundation offers the Biomarkers to Support Therapeutic Trials Program to fund outcome measures which will directly inform and transform therapeutic development. Funding is up to \$300,000.																																																						
Applicant Types																																																							
Funding Limit	300,000.00 maximum																																																						
Limited Submission	No																																																						
076236	General Research Grants	Friedreich's Ataxia Research Alliance		15-Aug-2022	250,000 USD																																																		
	<table border="0" style="width: 100%;"> <tr> <td style="width: 25%;">Contact Name</td> <td colspan="4"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="4">484-879-6160</td> </tr> <tr> <td>Contact Email</td> <td colspan="4">info@curefa.org</td> </tr> <tr> <td>Sponsor Website</td> <td colspan="4">Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td colspan="4">Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="4">15-Aug-2022 , 15-Oct-2022</td> </tr> <tr> <td>Synopsis</td> <td colspan="4">FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open</td> </tr> </table>					Contact Name					Contact Telephone	484-879-6160				Contact Email	info@curefa.org				Sponsor Website	Link to sponsor website				Program URL	Link to program URL				Deadline Dates (ALL)	15-Aug-2022 , 15-Oct-2022				Synopsis	FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open																		
Contact Name																																																							
Contact Telephone	484-879-6160																																																						
Contact Email	info@curefa.org																																																						
Sponsor Website	Link to sponsor website																																																						
Program URL	Link to program URL																																																						
Deadline Dates (ALL)	15-Aug-2022 , 15-Oct-2022																																																						
Synopsis	FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open																																																						

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$125,000 per year for one or two years.</p> <p>Applicant Types</p> <p>Funding Limit 125,000.00 per year</p> <p>Limited Submission No</p>				
073959	Research Grants	Gerber Foundation		15-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 231-924-3175</p> <p>Contact Email tgf@gerberfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Aug-2022 , 15-Nov-2022 [LOI/Pre-App], 15-Feb-2023</p> <p>Synopsis The Gerber Foundation provides support for studies to improve the nutrition and/or health of infants and toddlers. The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
013935	Premier's Science Fellowship Program	Government of Western Australia		23-Aug-2022	Not Specified
	<p>Contact Name Dr Ros Dilworth</p> <p>Contact Telephone 61 8 6552 6080</p> <p>Contact Email ros.dilworth@jtsi.wa.gov.au</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 23-Aug-2022 Synopsis The Premier's Science Fellowship Program aims to attract Premier's Science Fellows (distinguished researchers and leaders of international prominence) and Premier's Early to Mid-Career Fellows (supporting early to mid-career researchers) to Western Australia. Applicant Types Funding Limit 0.00 see detail Limited Submission Yes				
022177	Young Investigators Groups	Helmholtz Association		26-Aug-2022	787,500 USD
	Contact Name Anne Einhäupl, Head of President's Office Contact Telephone +49 30 206329-42 Contact Email anne.einhaeupl@helmholtz.de Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Aug-2022 Synopsis The Helmholtz Young Investigator Groups offer early scientific independence to international top talents. The funding generally amounts to at least € 300,000 p.a. for five years with an option of a permanent position in case of a positive evaluation. Applicant Types Funding Limit 150,000.00 per year Limited Submission No				
011401	BioMatrix Mike Hylton Memorial Scholarship	Hemophilia Federation of America		01-Aug-2022	1,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 202-675-6984</p> <p>Contact Email scholarship@hemophiliafed.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The purpose of this scholarship is to assist men with Hemophilia or von Willebrand Disease and their immediate family members with their further education.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 maximum</p> <p>Limited Submission No</p>				
011385	BioMatrix Millie Gonzalez Memorial Scholarship	Hemophilia Federation of America		01-Aug-2022	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-675-6984</p> <p>Contact Email scholarship@hemophiliafed.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The BioMatrix Millie Gonzalez Memorial Scholarship is awarded to women diagnosed with Hemophilia or von Willebrand Disease.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 maximum</p> <p>Limited Submission No</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
084304	Seed Grant Program	Hirshberg Foundation for Pancreatic Cancer Research		15-Aug-2022	40,000 USD
	Contact Name				
	Contact Telephone	310-473-5121			
	Contact Email	info@pancreatic.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Aug-2022			
	Synopsis	The Foundation Seed Grant program provides research support to basic and clinical scientists and investigators in the United States and overseas. The goals of the program are: To provide start-up funding for basic scientists and clinicians who intend to test innovative ideas for improving diagnosis and to develop new treatment modalities for pancreatic cancer. To obtain preliminary data required for additional funding from other agencies for pancreatic cancer research. To impact on the understanding of pancreatic cancer cell biology, biochemistry, physiology, morphology and response to therapy. To establish collaborations within the field for mutual projects that can be considered for further funding.			
	Applicant Types				
	Funding Limit	40,000.00 maximum			
	Limited Submission	No			
057155	Grants Program	Hofmann (Kent Richard) Foundation		05-Aug-2022 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	917-573-0486			
	Contact Email	krhofmann@gmail.com			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 05-Aug-2022 [LOI/Pre-App], 02-Sep-2022 Synopsis The Kent Richard Hofmann Foundation is a small, private foundation dedicated to the fight against HIV and AIDS. Grants are made semi-annually, to non-profit organizations, in support of care and direct services, education, and research. Applicant Types Funding Limit 0.00 not provided Limited Submission No				
060630	Building Better Futures for Health Challenge	IDE Group		25-Aug-2022	20,700 USD
	Contact Name Contact Telephone +61 2 9647 2660 Contact Email bbfhchallenge@idegroup.com.au Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 25-Aug-2022 Synopsis The BBFH Challenge offers an opportunity for startups and entrepreneurs to present ideas in front of a panel of medtech industry leaders and gain insight on best practice design and commercialisation for medical device technologies. Applicant Types Funding Limit 30,000.00 maximum Limited Submission No				
007141	ILCF Fellowship and Young Investigator Awards	International Association for the Study of Lung Cancer		31-Aug-2022	50,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 1-855-464-2752</p> <p>Contact Email foundation@iaslc.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis The International Association for the Study of Lung Cancer (IASLC) offers both Young Investigator Awards and Fellowships through the International Lung Cancer Foundation (ILCF). Young Investigator Grants and Fellowship Grants provide \$50,000 for a one-year research projects. Opportunities are numerous and based on geographic region of applicant.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
099003	LCFA/BMS/ILCF Young Investigator Award	International Lung Cancer Foundation		31-Aug-2022	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone 1-720-598-1952</p> <p>Contact Email foundation@iaslc.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis Lung Cancer Foundation of America (LCFA) and the International Lung Cancer Foundation (ILCF), together with financial support from Bristol-Myers Squibb (BMS), seek applications for the LCFA/BMS/ILCF Young Investigator Research Award (Award) in Translational Immuno-oncology.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 100,000.00 per year Limited Submission No				
058341	ISPAD - JDRF Research Fellowship	International Society for Pediatric and Adolescent Diabetes (ISPAD)		28-Aug-2022	25,000 USD
	Contact Name Contact Telephone +49 (0)30 24603-210 Contact Email secretariat@ispad.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 28-Aug-2022 Synopsis This grant is for ISPAD members below the age of 40 who wish to pursue a career in diabetes related research. It will cover USD 25,000 in research related expenses. The applicant needs to submit a scientific project which can be - at least partially - accomplished in the given time frame. Applicant Types Funding Limit 25,000.00 maximum Limited Submission No				
019902	Lillian Jean Kaplan International Prize	International Society of Nephrology (ISN)		29-Aug-2022	Not Specified
	Contact Name Jo-Ann Donner Contact Telephone 567-248-9703 Contact Email jdonner@theisn.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 29-Aug-2022 Synopsis The Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease (PKD), recognizes individual(s) exhibiting excellence and leadership in PKD clinical or basic research and whose seminal scientific work constitutes tangible achievement toward improving knowledge and treatment of PKD. Applicant Types Funding Limit 0.00 not provided Limited Submission No				
007135	ISPAD-JDRF Research Fellowship	International Society of Pediatric and Adolescent Diabetes		28-Aug-2022	25,000 USD
	Contact Name Contact Telephone +49 30 24603210 Contact Email secretariat@ispad.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 28-Aug-2022 Synopsis The ISPAD-JDRF Research Fellowship is for ISPAD members below the age of 40 who wish to pursue a career in diabetes related research. It will cover USD 25,000 in research related expenses. The applicant needs to submit a scientific project which can be - at least partially - accomplished in the given time frame. Applicant Types Funding Limit 25,000.00 maximum Limited Submission No				
024381	Large Research Grant (LG)	International Team for Implantology (ITI)		31-Aug-2022	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone +41 (0) 79 749 40 84</p> <p>Contact Email research@iti.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis The ITI provides funding for research projects in the field of implant dentistry and related areas that the ITI Research Committee has judged deserving of support. Part of the ITI's annual research budget is allocated to applications whose projects deal with specific areas of interest defined by the ITI Research Committee. Large grants will be awarded to experienced researchers/research groups only.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
024380	Small Research Grants (SG)	International Team for Implantology (ITI)		31-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +41 (0) 79 749 40 84</p> <p>Contact Email research@iti.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis Small grants are primarily intended for young researchers who have been working within established groups and wish to expand their scope and level of responsibility or want to establish a track record in implant dentistry.</p> <p>Applicant Types</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 not provided			
	Limited Submission	No			
020457	Geoffrey Phillips Analytical Science Award	Joint Pharmaceutical Analysis Group (JPAG)		31-Aug-2022	1,220 USD
	Contact Name				
	Contact Telephone	020 7572 2326			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Aug-2022			
	Synopsis	The Geoffrey Phillips Analytical Science Award will be awarded for the best oral presentation by a PhD student, post-Doctoral Fellow or young scientist currently carrying out research on an innovative application of pharmaceutical analytical science. This year's Award will be made to the presenter of the best short paper in pharmaceutical analysis at the JPAG Pharmaceutical analysis research awards virtual event in November.			
	Applicant Types				
	Funding Limit	1,000.00 maximum			
	Limited Submission	No			
021422	Grant Programs - Medical Research Phase I Application	Keck (W. M.) Foundation		15-Aug-2022	5,000,000 USD
	Contact Name	Melissa Gage, Program Coordinator			
	Contact Telephone	213-612-2000			
	Contact Email	Research@wmkeck.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Aug-2022 , 01-Nov-2022 [LOI/Pre-App], 15-Feb-2023</p> <p>Synopsis The Medical Research Program seeks to support pioneering discoveries in medical research by funding the high-risk/high-impact work of leading researchers, laying the groundwork for new paradigms, technologies and discoveries that will save lives, provide innovative solutions, and add to our understanding of the world. Historically, grants range from \$500,000 to \$5 million and are typically \$2 million or less.</p> <p>Applicant Types </p> <p>Funding Limit 5,000,000.00 maximum</p> <p>Limited Submission Yes</p>				
068091	Grants Program	Kettering Family Foundation		01-Aug-2022 [LOI/Pre-App]	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 937-228-1021</p> <p>Contact Email info@ketteringfamilyphilanthropies.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022 [LOI/Pre-App], 15-Sep-2022</p> <p>Synopsis The Kettering Family Foundation (KFF) will consider activities in the following categories: Arts, Culture and Humanities Education Environment Health/Medical Human Services Public/Society Benefit</p> <p>Applicant Types </p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission Yes</p>				
010990	Pilot Grant Program	Lung Cancer Research Foundation		29-Aug-2022	150,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 212-588-1580</p> <p>Contact Email grants@lcrf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Aug-2022</p> <p>Synopsis The LCRF Pilot Grant Program supports innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and other research. 2021 LCRF pilot grants will provide \$150,000 over a period of two years.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 maximum</p> <p>Limited Submission No</p>				
082247	Lupus Innovation Award	Lupus Research Alliance		01-Aug-2022	300,000 USD
	<p>Contact Name Diomaris Gonzalez, Director of Grant Programs</p> <p>Contact Telephone 646-884-6056</p> <p>Contact Email dgonzalez@lupusresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The Lupus Innovation Award (LIA) provides up to \$150,000/year total costs for up to two years. It provides support for pioneering, high-risk, high-reward approaches to major challenges in lupus research. Special emphasis is placed on lupus studies exploring fundamental mechanisms, novel targets and pathways, novel technologies, and interdisciplinary approaches. Both early career and established investigators new to lupus with highly innovative</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>ideas are encouraged to apply. Early-stage investigators are eligible for an additional third year of funding contingent upon successful completion of the original grant.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 per year</p> <p>Limited Submission No</p>				
108006	Lupus Mechanisms and Targets Award	Lupus Research Alliance		01-Aug-2022	600,000 USD
	<p>Contact Name Diomaris Gonzalez, Director of Grant Programs</p> <p>Contact Telephone 646-884-6056</p> <p>Contact Email dgonzalez@lupusresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Aug-2022</p> <p>Synopsis The Lupus Mechanisms and Targets Award (LMTA) provides up to \$200,000/year total costs for up to three years to support highly meritorious research focused on the identification and/or investigation of molecular pathways or targets with the potential to lead to new or improved therapies for patients with lupus.</p> <p>Applicant Types</p> <p>Funding Limit 200,000.00 per year</p> <p>Limited Submission No</p>				
078716	Grants Program	Mallinckrodt (Edward Jr.) Foundation		01-Aug-2022	60,000 USD
	<p>Contact Name Becki Blankenship, Director</p> <p>Contact Telephone 618-520-2977</p> <p>Contact Email emjf.org@gmail.com</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022			
	Synopsis	The Edward Mallinckrodt, Jr. Foundation provides support early stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis or treatment of disease.			
	Applicant Types				
	Funding Limit	60,000.00 see detail			
	Limited Submission	Yes			
107872	Institutional Scholarships/Fellowships and Grants	Maryland Institute for Integrative Health		01-Aug-2022	2,400 USD
	Contact Name				
	Contact Telephone	410-888-9048			
	Contact Email	financialaid@muih.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Aug-2022 , 01-Dec-2022			
	Synopsis	<p>The sponsor offers scholarships and grants to both in-state and out-of-state students. Students who are interested in applying for one or more scholarships and or grants must submit an online application. Each scholarship and or grant will be based on the following including, but not limited to a specific program, need-based, or diversity.</p> <p>Scholarships/Fellowships range from \$750 to up to \$2400 per semester. To qualify for the scholarships and or grants, students must first be admitted to MUIH. MUIH is a distinctive community of integrative health scholars, practitioners, researchers, advocates, and leaders. It promotes whole-person and community health and wellness through a relationship-centered approach by integrating healing traditions and contemporary science; recognizing the interconnection of mind, body, and spirit; acknowledging the wisdom of nature as a teacher; and being a healing presence in the world. Through discovery and exploration, MUIH delivers progressive educational programs as</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>pathways to fulfilling and impactful careers, uses evidence-informed practice and innovative clinical models to provide personalized care, and builds mutually beneficial partnerships to serve the needs of the community.</p> <p>2,400.00 see detail</p> <p>No</p>			
012626	Cardiovascular Diseases Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		01-Aug-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Lisa Hofschulte, Education Coordinator</p> <p>507-284-3304</p> <p>hofschulte.lisa2@mayo.edu</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Aug-2022</p> <p>The Cardiovascular Diseases Fellowship on Mayo Clinic's campus in Rochester, Minnesota, is a three-year program designed to prepare you for a career in academic medicine. The first 24 months of fellowship training will satisfy the American College of Cardiology's Core Cardiovascular Training Statement (COCATS) requirements for cardiovascular diseases.</p> <p></p> <p>0.00 see detail</p> <p>No</p>			
012586	Cardiology, Echocardiology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		31-Aug-2022	Not Specified
	Contact Name	Tammy Markham, Education Coordinator			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 507-266-4930</p> <p>Contact Email tmarkham@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis The one-year Echocardiology Fellowship at Mayo Clinic in Rochester, Minnesota, provides an opportunity for fellows to develop proficiency in performing and interpreting echocardiographic studies as they apply to cardiovascular diseases. The program also focuses on helping fellows gain understanding of echocardiographic and Doppler methods of assessing cardiovascular diseases. It is anticipated that one or two fellows will complete this program annually.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
012565	Cardiology, Advanced Adult Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		31-Aug-2022	Not Specified
	<p>Contact Name Tamara Markham, Education Coordinator</p> <p>Contact Telephone 507-266-4930</p> <p>Contact Email tmarkham@mayo.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Aug-2022</p> <p>Synopsis The Advanced Adult Cardiology Fellowship will provide the fellow and opportunity to develop competency in the specific subspecialization area. The training program can be customized to meet a fellow's individual career goals. Fellows will work closely with a highly experienced and knowledgeable clinical and research faculty. It is anticipated that one or two fellows will complete training in this program annually.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission No				
012630	Cardiovascular Diseases Fellowship (Florida)	Mayo Clinic College of Medicine and Science		31-Aug-2022	Not Specified
	Contact Name Brian Shapiro, M.D., Program Director Contact Telephone Contact Email shapiro.brian@mayo.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Aug-2022 Synopsis Mayo Clinic's campus in Jacksonville, Florida, offers a three-year Cardiovascular Diseases Fellowship that offers excellent clinical teaching from experts in bedside medicine, cardiac catheterization and intervention, electrophysiology, advanced heart failure, valvular and structural heart disease, vascular disease, echocardiography, advanced cardiac imaging, adult congenital heart disease, cardiac surgery, preventive cardiology, and cardiac rehabilitation. Opportunities for advanced training at our institution are also available in heart failure/transplant, as well as electrophysiology, which was recently approved to start by our institution and is currently going through the ACGME accreditation process. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
012606	Cardiology, Advanced Heart Failure and Transplant Cardiology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		01-Aug-2022	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Tamara Markham, Education Coordinator
Contact Telephone	507-266-4930
Contact Email	tmarkham@mayo.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Aug-2022
Synopsis	The Advanced Heart Failure and Transplant Cardiology Fellowship at Mayo Clinic in Rochester, Minnesota, is designed to provide intensive experience and training in the evaluation and treatment of patients with advanced heart failure. It is anticipated that two trainees will complete this program annually.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No